Preparation method of fused pyridone compounds as kras inhibitors, intermediates and preparation methods thereof
Patent Information
- Application Number
- TW114121716
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2025-06-04
- Filing Date
- 2025-06-10
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2045-06-09
AI Technical Summary
Existing methods for preparing KRAS inhibitors are lengthy, costly, and have low yields, with complex reactions that pose quality control challenges and risks.
A method involving a simplified synthetic route for preparing fused pyridone compounds as KRAS inhibitors, utilizing ring-closing and hydrolysis reactions with specific reagents and conditions to enhance yield and safety while avoiding nitration and hydrogenation steps.
The method achieves a high yield, reduces costs, and ensures a safer, more controlled synthesis process for KRAS inhibitors.
Abstract
Description
Technical Field
[0001] This invention claims the following priority: Application number CN2024107501438, application date: June 11, 2024; Application number CN2025107415102, application date: June 4, 2025. Prior Technology
[0002] The KRAS gene mutation rate in Asian populations is 10%–15%. KRAS is mutated in many cancers and is one of the major oncogenes. KRAS-mutant tumors are the most potentially targeted molecular subtype of non-small cell lung cancer (NSCLC), with a mutation rate of approximately 15%–25% in NSCLC. In NSCLC cases, KRAS mutations mainly occur at codons 12 and 13. The most common codon variation, accounting for approximately 39% of KRAS-mutant NSCLCs, is the KRAS-G12C mutation.
[0003] In lung adenocarcinoma, the KRAS gene positivity rate is 1 / 5 to 1 / 4, second only to EGFR positivity. The lack of targeted inhibitors makes treatment and prognosis extremely difficult for KRAS-positive non-small cell lung cancer patients. Lung cancer patients must undergo KRAS gene testing before receiving EGFR-TKI treatment; the decision to use EGFR-TKI targeted drugs as a clinical treatment measure is based on the test results. If the KRAS gene is mutated, molecular targeted therapy with EGFR-TKIs is not recommended.
[0004] Studies have shown that fused pyridinone compounds can be used as KRAS inhibitors. Traditional synthetic routes require the introduction of methoxy and demethoxy protection, involving multiple linear synthesis steps and resulting in low yields. The reactants... Introducing the compound using palladium-catalyzed coupling is costly; the synthesized intermediate compound Having two chiral axes is detrimental to quality control, the reaction is complex, and the yield is low; using acrylamide chloride as an acrylamide hydride reagent is also detrimental to quality control, the reaction is complex, and the yield is low; performing chiral separation in the final step is detrimental to the quality control of the active pharmaceutical ingredient, and the compound... They are a pair of diastereomers, and chiral separation by supercritical chromatography (SFC) is required to obtain the final free base compound, which further increases the synthesis cost.
[0005] Other traditional synthetic methods introduce a nitro group onto a fused pyridinone via nitration or reaction with nitroacetylamine to prepare a product containing... The intermediate compound of the structure is then further hydrogenated. Hydrogenation and cyclization synthesis The nitration and hydrogenation reactions both have relatively high risk indices.
[0006] Therefore, it is crucial to design a method for preparing KRAS inhibitors that is short in reaction, high in yield, mild and safe in reaction, and low in cost. Summary of the Invention
[0007] The technical problem this invention aims to solve is to overcome the technical defects of existing methods for preparing KRAS inhibitors and their intermediates, such as long synthetic routes, high costs, low yields, and high reaction risks. This invention provides a method for preparing fused pyridone compounds as KRAS inhibitors, as well as intermediates and their preparation methods. Compared with existing technologies, the preparation method provided by this invention has at least one of the following advantages: short reaction route, low cost, high yield, avoidance of nitration and hydrogenation reactions, mild and safe reaction, and good application prospects.
[0008] In one aspect of the present invention, a method for preparing a compound of formula A2 or an optical isomer thereof is provided, comprising the following steps: Compound A2 is prepared by contacting compound A1 and compound Z1. Wherein, R1 and R2 are independently selected from -H, -F, -Cl, -Br, or -I, respectively; R3 is selected from -F, -Cl, -Br, or -I; R4 is selected from ethyl, n-propyl, isopropyl, n-butyl, dibutyl, isobutyl, or tert-butyl.
[0009] In some embodiments of the present invention, R2 is preferably -Cl or -F; and / or R1 is preferably -Cl or -Br; and / or R3 is preferably -Cl or -F.
[0010] In some embodiments of the present invention, R4 is preferably ethyl, n-propyl, or isopropyl.
[0011] In some embodiments of the present invention, the preparation of the compound of formula A2 includes the following steps: first activating the carboxyl group of the compound of formula A1, and then contacting it with the compound of formula Z1 to carry out a ring-closing reaction to form an oxazole ring.
[0012] In this invention, the carboxyl activation in the above steps can be performed using reactions conventional in the art, such as acetylation or azide reaction.
[0013] In some embodiments of the present invention, the preparation of the compound of formula A2 includes the following steps: S1. Acrylating the compound of formula A1 with a acetylation reagent to prepare a acetylated compound; or acrylating the compound of formula A1 with an azide reagent to prepare an acetylated azide intermediate; S2. The acetohalogen compound or the acetoazide intermediate is subjected to a ring-closure reaction with the compound of formula Z1 to form an acetazole ring, thereby preparing the compound of formula A2.
[0014] In this invention, the conditions and operations in the acetylation reaction, azide reaction in step S1 and the cyclization reaction in step S2 are all conventional conditions and operations in the art.
[0015] The following conditions and operations are particularly preferred in this invention: In step S1, the preferred method for preparing the acetic acid compound is as follows: the compound of formula A1 and a acetic acid reagent are subjected to a acetic acid reaction in a solvent to prepare the acetic acid compound; The acetic agent is preferably one or more of oxalichlor and sulfonium chloride; The acetic acidifying agent is preferably oxalichlor; The molar ratio of the compound of formula A1 to the acetic agent is preferably 1:(0.5~1.5), including but not limited to 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, and 1:1.5.
[0016] The solvent is preferably one or more of ether solvents and halogenated hydrocarbon solvents. The ether solvent may be one or more of tetrahydrofuran, diethyl ether, and dioxane. The halogenated hydrocarbon solvent may be one or more of dichloromethane and trichloromethane. In a specific example of the present invention, the solvent is a mixture of tetrahydrofuran and dichloromethane.
[0017] The acylation reaction is carried out in the presence of a catalyst. The catalyst is preferably N,N-dimethylformamide.
[0018] The acetylation reaction temperature can be a conventional reaction temperature for this type of reaction, such as room temperature. The acetylation reaction temperature can be 10℃~30℃. Understandably, the acetylation reaction temperature includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0019] The acylation reaction process can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A1. The preferred acylation reaction time is 1 to 6 hours, for example, 3 hours.
[0020] In step S2, the preferred method for preparing compound A2 is as follows: in a solvent and in the presence of a base, the acetic acid halide compound is subjected to a cyclization reaction with compound Z1 to prepare compound A2; The molar ratio of the acetic acid compound to the compound of formula Z1 is preferably 1:(0.6~1.6), including but not limited to 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, and 1:1.6.
[0021] The base is preferably an organic amine base. The organic amine base may be triethylamine.
[0022] The solvent is preferably a nitrile solvent. The nitrile solvent may be acetonitrile.
[0023] The ring-closing reaction temperature can be a conventional reaction temperature for this type of reaction, such as room temperature. The ring-closing reaction temperature can be between 10℃ and 30℃. Understandably, the ring-closing reaction temperature includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0024] The progress of the ring-closing reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of the acetic acid halide compound. The preferred ring-closing reaction time is 6 to 18 hours, for example, 12 hours.
[0025] In another aspect, the present invention also provides a compound of formula A2 or an optical isomer thereof: The definitions of R1 to R4 are as described above.
[0026] In some embodiments of the present invention, the compound of formula A2 is selected from... , , , , , , or .
[0027] In another aspect, the present invention also provides a method for preparing a compound of formula A3 or its optical isomer, comprising the following steps: Compound A2 was hydrolyzed to prepare compound A3. The definitions of R1 to R4 are as described above.
[0028] In this invention, the conditions and operations in the hydrolysis reaction in the above steps are all conventional conditions and operations in the art.
[0029] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing compound A3 is as follows: in a solvent and in the presence of a base, compound A2 is subjected to a hydrolysis reaction to prepare compound A3; The alkali is preferably lithium hydroxide monohydrate.
[0030] The molar ratio of the compound of formula A2 to the base is preferably 1:(1.5~2.5), including but not limited to 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, and 1:2.5.
[0031] The solvent is preferably one or more of an ether solvent and water. The ether solvent may be tetrahydrofuran. In a specific example of the present invention, the solvent is a mixture of tetrahydrofuran and water.
[0032] The hydrolysis reaction temperature can be a conventional reaction temperature for this type of reaction, such as room temperature. The hydrolysis reaction temperature can be between 10℃ and 30℃. Understandably, the hydrolysis reaction temperature includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0033] The hydrolysis reaction can be monitored using conventional methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), with the reaction endpoint generally defined as the disappearance or cessation of reaction of compound A2. The hydrolysis reaction time is preferably 1 to 6 hours, for example, 3 hours.
[0034] In another aspect, the present invention also provides a method for preparing a compound of formula A4 or its optical isomer, comprising the following steps: S1. Hydrolyze compound A2 to prepare compound A3; S2. The compounds of formula A3 and Z2 are subjected to an amination reaction to prepare compound A4; The definitions of R1 to R4 are as described above; R5 and R6 are independently selected from -H, -F, -Cl, C1-6 alkyl or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy are optionally substituted with 1, 2 or 3 Ra. Each occurrence of R7 is independently selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl, or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy are optionally substituted by 1, 2, or 3 Ra; Each occurrence of Ra is independently selected from -H, -F, -Cl, -Br, -I, -OH, -NH2, -CH3, -CF3, -C2H5, -CN, -SF5, -CHO, -COOH, or -C(=O)NH2; m is selected from 0, 1, or 2.
[0035] In some embodiments of the present invention, R5 is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, secondary butyl, isobutyl or tertiary butyl; and / or R6 is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, secondary butyl, isobutyl or tertiary butyl.
[0036] In some embodiments of the present invention, in step S1 of the method for preparing compound A4 or its optical isomer, the conditions and operations for preparing compound A3 by hydrolyzing compound A2 are as described above.
[0037] In some embodiments of the present invention, in step S2 of the method for preparing the compound of formula A4 or its optical isomer, the preparation of the compound of formula A4 includes the following steps: S21. The compound of formula A3 and a acetylation reagent are subjected to a acetylation reaction to prepare a acetylated compound; S22. The acetic acid compound is subjected to a substitution reaction with the compound of formula Z2 to prepare the compound of formula A4.
[0038] In this invention, the conditions and operations in the acetylation reaction in step S21 and the substitution reaction in step S22 are conventional conditions and operations in the art.
[0039] The following conditions and operations are particularly preferred in this invention: In step S21, the preferred method for preparing the acetic acid compound is as follows: the compound of formula A3 and a acetic acid reagent are subjected to a acetic acid reaction in a solvent to prepare the acetic acid compound; The acetic agent is preferably oxalichlor.
[0040] The molar ratio of the compound of formula A3 to the acetylation reagent is preferably 1:(0.5~2), including but not limited to 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, and 1:2.
[0041] The solvent is preferably an ether solvent. The ether solvent may be one or more of tetrahydrofuran, diethyl ether, and dioxane. In a specific example of the present invention, the solvent is tetrahydrofuran.
[0042] The acylation reaction is carried out in the presence of a catalyst. The catalyst is preferably N,N-dimethylformamide.
[0043] The acetylation reaction temperature can be a conventional reaction temperature for this type of reaction, such as room temperature. The acetylation reaction temperature can be 10℃~30℃. Understandably, the acetylation reaction temperature includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0044] The acylation reaction process can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A1. The preferred acylation reaction time is 1 to 6 hours, for example, 3 hours.
[0045] In step S22, the preferred method for preparing the compound of formula A4 is as follows: in a solvent, in the presence of a base, the acetic acid halide compound is subjected to a substitution reaction with the compound of formula Z2 to prepare the compound of formula A4; The molar ratio of the acetic acid compound to the compound of formula Z2 is preferably 1:(0.6~1.6), including but not limited to 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, and 1:1.6.
[0046] The base is preferably an organic amine base. The organic amine base may be N,N-diisopropylethylamine.
[0047] The solvent is preferably an ether solvent. The ether solvent may be one or more of tetrahydrofuran, diethyl ether, and dioxane. In a specific example of the present invention, the solvent is tetrahydrofuran.
[0048] The temperature of the substitution reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the substitution reaction can be 10℃ to 30℃. Understandably, the temperature of the substitution reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0049] The progress of the substitution reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of the acetic acid compound. The substitution reaction time is preferably 6 to 18 hours, for example, 12 hours.
[0050] In another aspect, the present invention also provides a compound of formula A4 or an optical isomer thereof: The definitions of R1~R3, R5~R7 and m are as described above.
[0051] In some embodiments of the present invention, the compound of formula A4 is selected from... , , , , , , or .
[0052] In another aspect, the present invention also provides a method for preparing a compound of formula E5 or an optical isomer thereof, comprising the following steps: Compound E5 was prepared by cyclizing compound E3 with compound E4. Among them, R1~R2, R5~R7 and m are defined as described above; R4a is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, dibutyl, isobutyl, or tert-butyl.
[0053] In this invention, the conditions and operations in the addition cyclization reaction in the above steps are all conventional conditions and operations in the art.
[0054] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the E5 compound is as follows: in a solvent, the E3 compound and the E4 compound undergo an addition cyclization reaction to prepare the E5 compound; The solvent is preferably a halogenated hydrocarbon solvent. The halogenated hydrocarbon solvent may be chloroform.
[0055] The molar ratio of the E3 compound to the E4 compound is preferably 1:(1.5~2.5), including but not limited to 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, and 1:2.5.
[0056] The temperature of the addition cyclization reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the addition cyclization reaction can be 10℃ to 30℃. It is understood that the temperature of the addition cyclization reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0057] The progress of the addition cyclization reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compounds of formula E3 and E4. The preferred reaction time for the addition cyclization reaction is 6 to 24 hours, for example, 12 hours.
[0058] In another aspect, the present invention also provides a compound of formula E5 or an optical isomer thereof: The definitions of R1~R2, R5~R7, m, and R4a are as described above.
[0059] In some embodiments of the present invention, the compound of formula E5 is selected from... , , or .
[0060] In another aspect, the present invention also provides a method for preparing a compound of formula AA5 or an optical isomer thereof, comprising the following steps: Compound A4 was subjected to a nucleophilic substitution reaction to prepare compound AA5. Alternatively, the E5 compound can be contacted with a base to undergo an amino-ester exchange reaction, thus preparing the AA5 compound; The definitions of R1~R3, R5~R7, m, and R4a are as described above.
[0061] In this invention, the conditions and operations in the nucleophilic substitution and amine ester exchange reactions in the above steps are all conventional conditions and operations in the art.
[0062] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the AA5 compound is as follows: in a solvent, in the presence of a base, the A4 compound undergoes a nucleophilic substitution reaction to achieve cyclization and prepare the AA5 compound; The base is an inorganic base. The inorganic base may be cesium carbonate or sodium hydroxide.
[0063] The alkali is an organic alkali. The organic alkali may be sodium tert-butoxide.
[0064] The solvent is a acetylamine solvent. The acetylamine solvent may be N,N-dimethylformamide.
[0065] The temperature of the nucleophilic substitution reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the nucleophilic substitution reaction can be 10℃ to 30℃. Understandably, the temperature of the nucleophilic substitution reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0066] The progress of the nucleophilic substitution reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A4. The preferred reaction time is 1 to 6 hours, for example, 4 hours.
[0067] The preferred method for preparing the AA5 compound is as follows: in a solvent and in the presence of a base, the E5 compound is subjected to an amine-ester exchange reaction to achieve cyclization and prepare the AA5 compound; The base is an inorganic base. The inorganic base may be sodium hydroxide.
[0068] The solvent is preferably an ether solvent. The ether solvent may be tetrahydrofuran.
[0069] The molar ratio of the E3 compound to the base is preferably 1:(1.5~2.5), including but not limited to 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, and 1:2.5.
[0070] The temperature of the amino-ester exchange reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the amino-ester exchange reaction can be 10℃ to 30℃. Understandably, the temperature of the amino-ester exchange reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0071] The progress of the amino-ester exchange reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of the E5 compound. The preferred reaction time is 1 to 6 hours, for example, 5 hours.
[0072] In another aspect, the present invention also provides a compound of formula A5 or an optical isomer thereof: Among them, R1~R2, R5~R7 and m are defined as described above; R13 is selected from H or methyl.
[0073] In some embodiments of the present invention, the compound of formula A5 is selected from... , , , , , , or .
[0074] In some embodiments of the present invention, when R13 is methyl, the compound of formula A5 is prepared by the following manner: S1. The compound of formula AA5 is subjected to a hydrolytic ring-opening reaction to prepare the compound of formula A7'. S2. The compound of formula A7' is subjected to a cyclization reaction with substance P to prepare the compound of formula A5; wherein the substance P is selected from acetyl chloride, acetic anhydride or trimethyl orthoacetate.
[0075] In this invention, when R13 is methyl, the conditions and operations in the hydrolysis ring-opening reaction in step S1 and the cyclization reaction in step S2 of the preparation of compound A5 are conventional conditions and operations in the art.
[0076] The following conditions and operations are particularly preferred in this invention: When R13 is methyl, in step S1 of preparing compound A5, the preferred method for preparing compound A7' is as follows: in a solvent, compound A5 is subjected to a hydrolysis ring-opening reaction to prepare compound A7'; The solvent is preferably one or more of an acid and an alcohol. The acid may be hydrochloric acid. The alcohol may be one or more of methanol and ethanol. In a specific example of the present invention, the solvent is a mixture of hydrochloric acid and methanol.
[0077] The temperature of the hydrolysis ring-opening reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the hydrolysis ring-opening reaction can be 10℃~30℃. It is understood that the temperature of the hydrolysis ring-opening reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0078] The progress of the hydrolysis ring-opening reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound AA5. The preferred hydrolysis ring-opening reaction time is 1 to 6 hours, for example, 4 hours.
[0079] In another aspect, the present invention also provides a method for preparing a compound of formula A5-P or its optical isomer, comprising the following steps: Compound A5-P was prepared by coupling reaction of compound A5 with compound Z3-1; The definitions of R1~R2, R5~R7, m, and R13 are as described above; RZ is selected from H; R10 and R11 are each independently selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy groups are optionally substituted with 1, 2 or 3 Rb groups; Each occurrence of R12 is independently selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl, or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy groups are optionally substituted with 1, 2, or 3 Rb groups; Each occurrence of Rb is independently selected from -H, -F, -Cl, -Br, -I, -OH, -NH2, -CH3, -CF3, -C2H5, -CN, -SF5, -CHO, -COOH, or -C(=O)NH2; n is selected from 0, 1, 2 or 3.
[0080] In another aspect, the present invention also provides a method for preparing a compound of formula A5-P or an optical isomer thereof, comprising the following steps: performing a coupling reaction between a compound of formula A5 and a compound of formula Z3 to prepare a compound of formula A5-P; Wherein, the Z3 compound is a compound of formula Z3-1 or formula Z3-2; ; The definitions of R1~R2 are as described above; the definitions of R5~R7 and m are as described above; the definition of R13 is as described above. Each occurrence of RZ is independently selected from H or C1-6 alkyl groups, wherein the C1-6 alkyl group is optionally substituted with 1, 2, or 3 Rb groups; R10 and R11 are each independently selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy groups are optionally substituted with 1, 2 or 3 Rb groups; Each occurrence of R12 is independently selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl, or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy groups are optionally substituted with 1, 2, or 3 Rb groups; Each occurrence of Rb is independently selected from -H, -F, -Cl, -Br, -I, -OH, -NH2, -CH3, -CF3, -C2H5, -CN, -SF5, -CHO, -COOH, or -C(=O)NH2; n is selected from 0, 1, 2 or 3.
[0081] In some embodiments of the present invention, R10 is preferably -H, -F, -Cl, -Br or hydroxyl; and / or R11 is preferably -H, -F, -Cl, -Br or hydroxyl.
[0082] In this invention, the conditions and operations in the coupling reaction of the above steps are all conventional conditions and operations in the art.
[0083] In another aspect, the present invention also provides a compound of formula A5-P or an optical isomer thereof: The definitions of R2, R5~R7, m, R13, R10~R12 and n are as described above.
[0084] In some embodiments of the present invention, the compound of formula A5-P is selected from... , , or .
[0085] In another aspect, the present invention also provides a method for preparing a compound of formula A6, a compound of formula D6, or an optical isomer thereof, comprising the following steps: Compound A5 and substance L are contacted and chirally resolved to prepare compound A6 or compound D6. The definitions of R1~R2, R5~R7, m, and R13 are as described above; The substance L is one or more selected from S-binaphthol phosphate, D-3-bromocamphor-10-sulfonic acid, D-(+)-camphor sulfonic acid, S-3,3'-bis(triphenylsilyl)binaphthol phosphonate, S-3,3'-bis(3,5-bistrifluoromethoxyphenyl)-1,1'-bi-(2-naphthol) phosphate, and S-3,3'-bis(2,4,6-triisopropylphenyl)-1,1'-binaphthol-2,2'-bisphosphate. Or one or more of the following: R-binaphthol phosphate, L-3-bromocamphor-10-sulfonic acid, L-(+)-camphor sulfonic acid, R-3,3'-bis(triphenylsilyl)binaphthol phosphonate, R-3,3'-bis(3,5-bistrifluoromethoxyphenyl)-1,1'-binaphthol phosphate and R-3,3'-bis(2,4,6-triisopropylphenyl)-1,1'-binaphthol-2,2'-bisphosphate.
[0086] In some embodiments of the present invention, the substance L may be S-binaphthol phosphate.
[0087] In some embodiments of the present invention, the substance L is preferably R-binaphthol phosphate.
[0088] In some embodiments of the present invention, the chiral splitting includes the following steps: S1. A salt-forming reaction is carried out between compound A5 and substance L to prepare a salt-type intermediate compound; S2. The salt-type intermediate compound is reacted with a free reagent to prepare compound A6 or compound D6.
[0089] In this invention, the conditions and operations in the salt formation reaction in step S1 and the free reaction in step S2 are conventional conditions and operations in the art.
[0090] The following conditions and operations are particularly preferred in this invention: In the chiral resolution step S1, the preferred method for preparing the salt-type intermediate compound is as follows: in a solvent, the compound of formula A5 and substance L undergo a salt-forming reaction to prepare the salt-type intermediate compound; The solvent may be one or more ketone solvents and water. The ketone solvent may be acetone. In a specific example of the present invention, the solvent is a mixture of acetone and water.
[0091] The solvent is preferably one or more of anisole and methanol; methanol can also be replaced by ethanol, ethyl acetate, methyl acetate, propyl acetate, or isopropyl acetate. In a specific example of the present invention, the solvent is a mixture of anisole and methanol.
[0092] The molar ratio of the compound of formula A5 to the substance L is preferably 1:(0.6~1.6), including but not limited to 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, and 1:1.6.
[0093] The temperature of the salt-forming reaction can be a conventional reaction temperature for this type of reaction. The temperature of the salt-forming reaction can be 10℃ to 50℃. Further, the preferred temperature of the salt-forming reaction is 10℃ to 40℃. It is understood that the temperature of the salt-forming reaction includes, but is not limited to, 10℃, 25℃, 30℃, 35℃, and 40℃.
[0094] The salt-forming reaction can be monitored using conventional methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), generally with the disappearance or cessation of the reaction of the free compound of formula A5 and the satisfactory chiral result of the resolved compound as the reaction endpoint. The preferred salt-forming reaction time is 3 to 60 hours. Further, the preferred salt-forming reaction time is 3 to 48 hours, for example, 4 hours.
[0095] In the chiral resolution step S2, the preferred method for preparing the compound of formula A6 or formula D6 is as follows: in a solvent, the salt-type intermediate compound is reacted with a free reagent to prepare the compound of formula A6 or formula D6; The free reagent is preferably an acid or a base. The base can be sodium hydroxide or triethylamine. In one specific example of the invention, the free reagent is a 30% sodium hydroxide solution. In another specific example of the invention, the free reagent is triethylamine.
[0096] The preferred molar ratio of the salt-type intermediate compound to the free reagent is 1:(0.5~1.5), including but not limited to 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, and 1:1.5.
[0097] The solvent is preferably a halogenated hydrocarbon solvent or an ester solvent. The halogenated hydrocarbon solvent can be dichloromethane, and the ester solvent can be ethyl acetate.
[0098] The temperature of the free reaction can be the conventional reaction temperature for this type of reaction.
[0099] In another aspect, the present invention also provides a compound of formula A6, a compound of formula D6, substance N, or an optical isomer thereof, wherein substance N comprises the compound of formula A6 and the compound of formula D6: The definitions of R1~R2, R5~R7, m, and R13 are as described above.
[0100] In some embodiments of the present invention, the compound of formula A6 is selected from... , , , , , , or .
[0101] In some embodiments of the present invention, the compound of formula D6 is selected from... , , , , , , or .
[0102] In some embodiments of the present invention, the substance N is selected from a mixture of any of the following groups: and mixture, and mixture, and mixture, and mixture, and mixture, and mixture, and mixture, and A mixture.
[0103] In another aspect, the present invention also provides a method for preparing a compound of formula A6-P, a compound of formula D6-P, or an optical isomer thereof, comprising the following steps: Compound A5-P and substance L are contacted and chirally resolved to prepare compound A6-P or compound D6-P; or Compound A6-P or compound D6 is prepared by coupling compound Z3-1 with compound D6-P. The definitions of R1~R2, R5~R7, m, R10~R12, n, and R13 are as described above; RZ is selected from H; The definition of substance L is as described above; The steps and conditions for chiral splitting are as described above.
[0104] In another aspect, the present invention also provides a method for preparing a compound of formula A6-P, a compound of formula D6-P, or an optical isomer thereof, comprising the following steps: Compound A5-P and substance L are contacted and chirally resolved to prepare compound A6-P or compound D6-P; or Compound A6-P or compound D6 is prepared by coupling compound Z3 with compound Z3. Wherein, the Z3 compound is a compound of formula Z3-1 or formula Z3-2; ; Each occurrence of RZ is independently selected from H or C1-6 alkyl groups, wherein the C1-6 alkyl group is optionally substituted with 1, 2, or 3 Rb groups; The definitions of R1~R2, R5~R7, m, R10~R12, n, and R13 are as described above; The definition of substance L is as described above; The steps and conditions for chiral splitting are as described above.
[0105] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the compound of formula A6-P is as follows: in a solvent, in the presence of a palladium catalyst, a ligand, and a base, the compound of formula A6 is coupled with the compound of formula Z3 to prepare the compound of formula A6-P; The preferred molar ratio of the compound of formula A6 to the compound of formula Z3 is 1:(0.9~5), including but not limited to 1:0.9, 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2, 1:3, 1:4, and 1:5. The solvent is preferably one or more of 1,4-dioxane, DMSO, DMF, tetrahydrofuran, toluene, acetonitrile, and water; Preferably, the alkali is selected from one or more of dipotassium hydrogen phosphate, cesium carbonate, potassium carbonate, sodium carbonate, and triethylamine; The molar ratio of the compound of formula A6 to the base is preferably 1:(1~6), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The palladium catalyst is preferably palladium acetate; The preferred molar ratio of the compound of formula A6 to the palladium catalyst is 1:(0.001~0.5), including but not limited to 1:0.001, 1:0.005, 1:0.01, 1:0.05, 1:0.1, 1:0.2, 1:0.3, 1:0.4, and 1:0.5. The ligand is preferably triphenylphosphine; The preferred molar ratio of the compound of formula A6 to the ligand is 1:(0.001~0.5), including but not limited to 1:0.001, 1:0.005, 1:0.01, 1:0.05, 1:0.1, 1:0.2, 1:0.3, 1:0.4, and 1:0.5. The temperature of the coupling reaction can be a conventional reaction temperature for this type of reaction. The temperature of the coupling reaction can be 40℃~100℃, including but not limited to 40℃, 50℃, 60℃, 70℃, 80℃, 90℃, and 100℃.
[0106] The process of the coupling reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A6.
[0107] In another aspect, the present invention also provides a compound of formula A6-P, a compound of formula D6-P, a substance M, or an optical isomer thereof, wherein the substance M comprises the compound of formula A6-P and the compound of formula D6-P: The definitions of R2, R5~R7, m, R10~R12, n, and R13 are as described above.
[0108] In some embodiments of the present invention, the compound of formula A6-P is selected from... , , or .
[0109] In some embodiments of the present invention, the compound of formula D6-P is selected from... , , or .
[0110] In some embodiments of the present invention, the substance M is selected from a mixture of any of the following groups: and mixture, and mixture, and mixture, and A mixture.
[0111] In another aspect, the present invention also provides a method for preparing a compound of formula A7', its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: The compound of formula A5 is subjected to a hydrolytic ring-opening reaction to prepare the compound of formula A7' or its pharmacologically acceptable salt; The definitions of R1~R2, R5~R7, m, and R13 are as described above.
[0112] In this invention, the conditions and operations in the hydrolysis ring-opening reaction in the above steps are all conventional conditions and operations in the art.
[0113] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the compound of formula A7' or a pharmacologically acceptable salt thereof is as follows: The compound of formula A5 is subjected to a hydrolytic ring-opening reaction in a solvent to prepare the compound of formula A7' or a pharmacologically acceptable salt thereof; The solvent is preferably one or more of an acid and an alcohol. The acid may be hydrochloric acid. The alcohol may be one or more of methanol and ethanol. In a specific example of the present invention, the solvent is a mixture of hydrochloric acid and methanol.
[0114] The temperature of the hydrolysis ring-opening reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the hydrolysis ring-opening reaction can be 10℃~30℃. It is understood that the temperature of the hydrolysis ring-opening reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0115] The progress of the hydrolysis ring-opening reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A5. The preferred hydrolysis ring-opening reaction time is 1 to 6 hours, for example, 4 hours.
[0116] In some embodiments of the present invention, the compound of formula A7' is prepared by neutralization reaction with a salt of formula A7' that is pharmacologically acceptable to the compound.
[0117] In another aspect, the present invention also provides a method for preparing a compound of formula A7, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Hydrolyze and ring-opening compound A6 to prepare compound A7 or its pharmacologically acceptable salt; or Pathway 2: Contacting the compound of formula A7' or its pharmacologically acceptable salt with a chiral acid to perform chiral resolution, thereby preparing the compound of formula A7 or its pharmacologically acceptable salt; The definitions of R1~R2, R5~R7, m, and R13 are as described above.
[0118] In this invention, the conditions and operations in the hydrolysis ring-opening reaction and chiral resolution in the above steps are all conventional conditions and operations in the art.
[0119] The following conditions and operations are particularly preferred in this invention: In path 1, the preferred method for preparing the compound of formula A7 or its pharmacologically acceptable salt is as follows: in a solvent, the compound of formula A6 is subjected to a hydrolysis ring-opening reaction to prepare the compound of formula A7 or its pharmacologically acceptable salt; The solvent is preferably one or more of an acid and an alcohol. The acid may be hydrochloric acid. The alcohol may be one or more of methanol and ethanol. In a specific example of the present invention, the solvent is a mixture of hydrochloric acid and methanol.
[0120] The temperature of the hydrolysis ring-opening reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the hydrolysis ring-opening reaction can be 10℃~30℃. It is understood that the temperature of the hydrolysis ring-opening reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0121] The progress of the hydrolysis ring-opening reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A6. The preferred hydrolysis ring-opening reaction time is 1 to 6 hours, for example, 4 hours.
[0122] In path 2, the preferred method for preparing the compound of formula A7 or its pharmacologically acceptable salt is as follows: in a solvent, the compound of formula A7' or its pharmacologically acceptable salt is contacted with a chiral acid to perform chiral resolution, thereby preparing the compound of formula A7 or its pharmacologically acceptable salt, or the compound of formula D7 or its pharmacologically acceptable salt; The chiral acid is preferably S-binaphthol phosphate or R-binaphthol phosphate. It is understood that in this invention, the chiral acid can be resolved in different systems to obtain a compound of formula A7 or a pharmacologically acceptable salt thereof, or a compound of formula D7 or a pharmacologically acceptable salt thereof. Optionally, the chiral acid is S-binaphthol phosphate. More preferably, the chiral acid is R-binaphthol phosphate.
[0123] In some embodiments of the present invention, the compound of formula A7 is prepared by neutralization reaction of a salt of formula A7 that is pharmacologically acceptable to the compound.
[0124] In another aspect, the present invention also provides a method for preparing a compound of formula A7-P, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Hydrolyze and ring-opening compound A6-P to prepare compound A7-P or its pharmacologically acceptable salt; or Pathway 2: A compound of formula A7 or its pharmacologically acceptable salt is coupled with a compound of formula Z3-1 to prepare a compound of formula A7-P or its pharmacologically acceptable salt; Among them, RZ is selected from H; the definitions of R2, R5~R7, m, R10~R12, n, and R13 are as described above.
[0125] In another aspect, the present invention also provides a method for preparing a compound of formula A7-P, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Hydrolyze and ring-opening compound A6-P to prepare compound A7-P or its pharmacologically acceptable salt; or Pathway 2: A coupling reaction is performed between compound A7 or its pharmacologically acceptable salt and compound Z3 to prepare compound A7-P or its pharmacologically acceptable salt; Wherein, the Z3 compound is a compound of formula Z3-1 or formula Z3-2; ; The definitions of R2, R5~R7, m, R10~R12, n, RZ, and R13 are as described above.
[0126] In this invention, the conditions and operations in the hydrolysis ring-opening reaction in path 1 and the coupling reaction in path 2 are conventional conditions and operations in the art.
[0127] In some embodiments of the present invention, the conditions and operation of the hydrolysis ring-opening reaction are as described above.
[0128] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the compound of formula A7-P is as follows: in a solvent, the compound of formula A6-P is subjected to a hydrolysis ring-opening reaction to prepare the compound of formula A7-P or its pharmacologically acceptable salt; The solvent is preferably one or more selected from ethanol hydrochloride, methanol hydrochloride, ethyl hydrochloride, and aqueous hydrochloric acid solution. The temperature of the hydrolysis ring-opening reaction can be the conventional reaction temperature for this type of reaction, such as room temperature.
[0129] The progress of the hydrolysis ring-opening reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A6-P.
[0130] In another aspect, the present invention also provides a method for preparing a compound of formula A7'-P, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Hydrolyze and ring-opening compound A5-P to prepare compound A7'-P or its pharmacologically acceptable salt; or Pathway 2: A compound of formula A7' or its pharmacologically acceptable salt is coupled with a compound of formula Z3-1 to prepare a compound of formula A7'-P or its pharmacologically acceptable salt; Among them, RZ is selected from H; the definitions of R2, R5~R7, m, R10~R12, n, and R13 are as described above.
[0131] In another aspect, the present invention also provides a method for preparing a compound of formula A7'-P, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Hydrolyze and ring-opening compound A5-P to prepare compound A7'-P or its pharmacologically acceptable salt; or Pathway 2: A compound of formula A7' or its pharmacologically acceptable salt is coupled with a compound of formula Z3 to prepare a compound of formula A7'-P or its pharmacologically acceptable salt; Wherein, the Z3 compound is a compound of formula Z3-1 or formula Z3-2; ; The definitions of R2, R5~R7, m, R10~R12, n, and R13 are as described above.
[0132] In this invention, the conditions and operations in the hydrolysis ring-opening reaction in path 1 and the coupling reaction in path 2 are conventional conditions and operations in the art.
[0133] In some embodiments of the present invention, the conditions and operation of the hydrolysis ring-opening reaction are as described above.
[0134] In another aspect, the present invention also provides a compound of formula A7, a compound of formula A7', a compound of formula A7-P, a compound of formula A7'-P, an optical isomer thereof, or a pharmacologically acceptable salt thereof: The definitions of R1~R2, R5~R7, m, R10~R12 and n are as described above.
[0135] In some embodiments of the present invention, the compound of formula A7 is selected from... , , or .
[0136] In some embodiments of the present invention, the compound of formula A7' is selected from... , , or .
[0137] In some embodiments of the present invention, the compound of formula A7-P is selected from... or .
[0138] In some embodiments of the present invention, the compound of formula A7'-P is preferably... or .
[0139] In another aspect, the present invention also provides a method for preparing a compound of formula A7-M, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: A compound of formula A7 or its pharmacologically acceptable salt is contacted with a halomethane to carry out a nucleophilic substitution reaction, thereby preparing a compound of formula A7-M or its pharmacologically acceptable salt; The definitions of R1~R2, R5~R7 and m are as described above.
[0140] In this invention, the conditions and operations in the nucleophilic substitution reaction in the above steps are all conventional conditions and operations in the art.
[0141] In another aspect, the present invention also provides a method for preparing a compound of formula A7-M, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Compound of formula A7 or its pharmacologically acceptable salt is contacted with a carbonyl-containing compound to carry out a ring-closure reaction, thereby preparing compound of formula A7-intermediate 1 or its pharmacologically acceptable salt; The A7-intermediate 1 compound or its pharmacologically acceptable salt is contacted with a methylating agent to carry out a methylation reaction, thereby preparing the A7-intermediate 2 compound or its pharmacologically acceptable salt; The compound of formula A7-intermediate 2 or its pharmacologically acceptable salt is hydrolyzed to prepare compound of formula A7-M or its pharmacologically acceptable salt. The definitions of R1~R2, R5~R7 and m are as described above.
[0142] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the compound of formula A7-intermediate 1 or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7 or its pharmacologically acceptable salt is contacted with a carbonyl-containing compound to carry out a ring-closure reaction, thereby preparing the compound of formula A7-intermediate 1 or its pharmacologically acceptable salt; The carbonyl-containing compound may be triphosgene or carbon dioxide; the carbonyl-containing compound is preferably triphosgene. The preferred molar ratio of the compound of formula A7 to the carbonyl-containing compound is 1:(0.5~1.5), including but not limited to 1:0.5, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, and 1:1.5. The solvent is preferably one or more selected from tetrahydrofuran, acetonitrile, dichloromethane, chloroform, methyl tert-butyl ether, and 1,4-dioxane; Preferably, the base is one or more selected from N,N-diisopropylethylamine, pyridine, triethylamine, and cesium carbonate; The molar ratio of the compound of formula A7 to the base is preferably 1:(1.5~8), including but not limited to 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, and 1:8; The ring-closing reaction temperature can be a conventional reaction temperature for this type of reaction. The ring-closing reaction temperature can be -30℃ to 30℃. It is understood that the ring-closing reaction temperature includes, but is not limited to, -30℃, -25℃, -20℃, -15℃, -10℃, 0℃, 10℃, 15℃, 20℃, 25℃, and 30℃. The progress of the ring-closing reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7.
[0143] The preferred method for preparing the compound of formula A7-intermediate 2 or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7-intermediate 1 or its pharmacologically acceptable salt is contacted with a methylating agent to carry out a methylation reaction, thereby preparing the compound of formula A7-intermediate 2 or its pharmacologically acceptable salt; The methylating agent is preferably one or more of halomethane and formaldehyde; further, the halomethane is preferably iodomethane. The molar ratio of the compound of formula A7-intermediate 1 to the methylating agent is preferably 1:(0.9~6), including but not limited to 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The solvent is preferably one or more selected from DMF, DMSO, NMP, acetonitrile, and tetrahydrofuran; The alkali is preferably one or more selected from cesium carbonate, potassium carbonate, sodium carbonate, potassium phosphate, and DBU; The molar ratio of the compound of formula A7-intermediate 1 to the base is preferably 1:(0.7~6), including but not limited to 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The temperature of the methylation reaction can be a conventional reaction temperature for this type of reaction, such as room temperature; The progress of the methylation reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7-intermediate 1.
[0144] The preferred method for preparing the compound of formula A7-M or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7-intermediate 2 or its pharmacologically acceptable salt is subjected to a hydrolysis reaction to prepare the compound of formula A7-M or its pharmacologically acceptable salt; The solvent is preferably one or more selected from tetrahydrofuran, methanol, and ethanol. The alkali is preferably one or more selected from lithium hydroxide, sodium hydroxide, and potassium hydroxide; The molar ratio of the compound of formula A7-intermediate 2 to the base is preferably 1:(1~8), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, and 1:8; The temperature of the hydrolysis reaction can be a conventional reaction temperature for this type of reaction, such as room temperature; The progress of the hydrolysis reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7-intermediate 2.
[0145] In another aspect, the present invention also provides a method for preparing a compound of formula A7'-M, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: A compound of formula A7' or its pharmacologically acceptable salt is contacted with a halomethane to carry out a nucleophilic substitution reaction, thereby preparing a compound of formula A7'-M or its pharmacologically acceptable salt; The definitions of R1~R2, R5~R7 and m are as described above.
[0146] In this invention, the conditions and operations in the nucleophilic substitution reaction in the above steps are all conventional conditions and operations in the art.
[0147] In another aspect, the present invention also provides a method for preparing a compound of formula A7'-M, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: The compound of formula A7' or its pharmacologically acceptable salt is contacted with a carbonyl-containing compound to carry out a ring-closure reaction, thereby preparing the compound of formula A7'-intermediate 1 or its pharmacologically acceptable salt; The A7'-intermediate 1 compound or its pharmacologically acceptable salt is contacted with a methylating agent to carry out a methylation reaction, thereby preparing the A7'-intermediate 2 compound or its pharmacologically acceptable salt; The compound of formula A7'-intermediate 2 or its pharmacologically acceptable salt is hydrolyzed to prepare compound of formula A7'-M or its pharmacologically acceptable salt; The definitions of R1~R2, R5~R7 and m are as described above.
[0148] In this invention, the conditions and operations in the cyclization reaction, methylation reaction and hydrolysis reaction in the above steps are all conventional conditions and operations in the art.
[0149] In another aspect, the present invention also provides a method for preparing a compound of formula A7-PM, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: A7-P compound or its pharmacologically acceptable salt is prepared by contacting a halomethane with a nucleophilic substitution reaction to carry out a nucleophilic substitution reaction; The definitions of R2, R5~R7, m, R10~R12 and n are as described above.
[0150] In this invention, the conditions and operations in the nucleophilic substitution reaction in the above steps are all conventional conditions and operations in the art.
[0151] In another aspect, the present invention also provides a method for preparing a compound of formula A7-PM, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: A compound of formula A7-P or its pharmacologically acceptable salt is contacted with a carbonyl-containing compound to carry out a ring-closure reaction, thereby preparing a compound of formula A7-P-intermediate 1 or its pharmacologically acceptable salt; The compound of formula A7-P-intermediate 1 or its pharmacologically acceptable salt is contacted with a methylating agent to carry out a methylation reaction, thereby preparing compound of formula A7-P-intermediate 2 or its pharmacologically acceptable salt; The compound of formula A7-P-intermediate 2 or its pharmacologically acceptable salt is prepared by hydrolysis. The definitions of R2, R5~R7, m, R10~R12 and n are as described above.
[0152] In this invention, the conditions and operations in the cyclization reaction, methylation reaction and hydrolysis reaction in the above steps are all conventional conditions and operations in the art.
[0153] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the A7-P-intermediate 1 compound or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the A7-P compound or its pharmacologically acceptable salt is contacted with a carbonyl-containing compound to carry out a ring-closure reaction, thereby preparing the A7-P-intermediate 1 compound or its pharmacologically acceptable salt; The carbonyl-containing compound may be triphosgene or carbon dioxide; the carbonyl-containing compound is preferably triphosgene. The preferred molar ratio of the A7-P compound to the carbonyl-containing compound is 1:(0.5~1.5), including but not limited to 1:0.5, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, and 1:1.5. The solvent is preferably one or more selected from tetrahydrofuran, acetonitrile, dichloromethane, chloroform, methyl tert-butyl ether, and 1,4-dioxane; Preferably, the base is one or more selected from N,N-diisopropylethylamine, pyridine, triethylamine, and cesium carbonate; The molar ratio of the compound of formula A7-P to the base is preferably 1:(1.5~8), including but not limited to 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, and 1:8; The ring-closing reaction temperature can be a conventional reaction temperature for this type of reaction. The ring-closing reaction temperature can be -30℃ to 30℃. It is understood that the ring-closing reaction temperature includes, but is not limited to, -30℃, -25℃, -20℃, -15℃, -10℃, 0℃, 10℃, 15℃, 20℃, 25℃, and 30℃. The progress of the ring-closing reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of compound A7-P.
[0154] The preferred method for preparing the compound of formula A7-P-intermediate 2 or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7-P-intermediate 1 or its pharmacologically acceptable salt is contacted with a methylating agent to carry out a methylation reaction, thereby preparing the compound of formula A7-P-intermediate 2 or its pharmacologically acceptable salt; The methylating agent is preferably one or more of halomethane and formaldehyde; further, the halomethane is preferably iodomethane. The molar ratio of the compound of formula A7-P-intermediate 1 to the methylating agent is preferably 1:(0.9~6), including but not limited to 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The solvent is preferably one or more selected from DMF, DMSO, NMP, acetonitrile, and tetrahydrofuran; The alkali is preferably one or more selected from cesium carbonate, potassium carbonate, sodium carbonate, potassium phosphate, and DBU; The molar ratio of the compound of formula A7-P-intermediate 1 to the base is preferably 1:(0.7~6), including but not limited to 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The temperature of the methylation reaction can be a conventional reaction temperature for this type of reaction, such as room temperature; The progress of the methylation reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7-P-intermediate 1. Wherein, when R10 and / or R11 are hydroxyl groups, after contacting the compound of formula A7-P-intermediate 1 or its pharmacologically acceptable salt with a methylating agent to carry out a methylation reaction, the method further includes the following step: subjecting the product of the methylation reaction to a demethylating agent to carry out a deprotection reaction to prepare the compound of formula A7-P-intermediate 2 or its pharmacologically acceptable salt; Furthermore, the demethylating agent is preferably one or more selected from aqueous solutions of hydrogen bromide, boron trichloride, and hydrochloric acid. Furthermore, the temperature of the deprotection reaction can be a conventional reaction temperature for this type of reaction. The temperature of the deprotection reaction can be 80℃~120℃, including but not limited to 80℃, 85℃, 90℃, 95℃, 100℃, 105℃, 110℃, 115℃, and 120℃.
[0155] The preferred method for preparing the compound of formula A7-PM or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7-P-intermediate 2 or its pharmacologically acceptable salt is subjected to a hydrolysis reaction to prepare the compound of formula A7-PM or its pharmacologically acceptable salt; The solvent is preferably one or more selected from tetrahydrofuran, methanol, and ethanol. The alkali is preferably one or more selected from lithium hydroxide, sodium hydroxide, and potassium hydroxide; The molar ratio of the compound of formula A7-intermediate 2 to the base is preferably 1:(1~8), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, and 1:8; The temperature of the hydrolysis reaction can be a conventional reaction temperature for this type of reaction, such as room temperature; The progress of the hydrolysis reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7-P-intermediate 2.
[0156] In another aspect, the present invention also provides a method for preparing a compound of formula A7-PM, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Compound of formula A7 or its pharmacologically acceptable salt is contacted with a carbonyl-containing compound to carry out a ring-closure reaction, thereby preparing compound of formula A7-PM-intermediate 1 or its pharmacologically acceptable salt; The compound of formula A7-PM-intermediate 1 or its pharmacologically acceptable salt is contacted with a methylating agent to carry out a methylation reaction, thereby preparing compound of formula A7-PM-intermediate 2 or its pharmacologically acceptable salt; Compound A7-PM-intermediate 2 or its pharmacologically acceptable salt is coupled with compound Z3 to prepare compound A7-PM-intermediate 3; The compound of formula A7-PM-intermediate 3 or its pharmacologically acceptable salt is prepared by hydrolysis. Wherein, the Z3 compound is a compound of formula Z3-1 or formula Z3-2; ; The definitions of R1~R2, R5~R7, m, R10~R12, RZ, and n are as described above.
[0157] In this invention, the conditions and operations in the cyclization reaction, methylation reaction, coupling reaction, and hydrolysis reaction in the above steps are all conventional conditions and operations in the art.
[0158] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the compound of formula A7-PM-intermediate 1 or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7 or its pharmacologically acceptable salt is contacted with a carbonyl-containing compound to carry out a ring-closure reaction, thereby preparing the compound of formula A7-PM-intermediate 1 or its pharmacologically acceptable salt; The carbonyl compound may be selected from triphosgene or carbon dioxide, preferably triphosgene; The preferred molar ratio of the compound of formula A7 to the carbonyl-containing compound is 1:(0.5~1.5), including but not limited to 1:0.5, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, and 1:1.5. The solvent is preferably one or more selected from tetrahydrofuran, acetonitrile, dichloromethane, chloroform, methyl tert-butyl ether, and 1,4-dioxane; Preferably, the base is one or more selected from N,N-diisopropylethylamine, pyridine, triethylamine, and cesium carbonate; The molar ratio of the compound of formula A7-P to the base is preferably 1:(1.5~8), including but not limited to 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, and 1:8; The ring-closing reaction temperature can be a conventional reaction temperature for this type of reaction. The ring-closing reaction temperature can be -30℃ to 30℃. It is understood that the ring-closing reaction temperature includes, but is not limited to, -30℃, -25℃, -20℃, -15℃, -10℃, 0℃, 10℃, 15℃, 20℃, 25℃, and 30℃. The progress of the ring-closing reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7.
[0159] The preferred method for preparing the compound of formula A7-PM-intermediate 2 or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7-PM-intermediate 1 or its pharmacologically acceptable salt is contacted with a methylating agent to carry out a methylation reaction, thereby preparing the compound of formula A7-PM-intermediate 2 or its pharmacologically acceptable salt; The methylating agent may be selected from one or more of halomethane and formaldehyde, wherein the halomethane is preferably iodomethane; The molar ratio of the compound of formula A7-P-intermediate 1 to the methylating agent is preferably 1:(0.9~6), including but not limited to 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The solvent is preferably one or more selected from DMF, DMSO, NMP, acetonitrile, and tetrahydrofuran; The alkali is preferably one or more selected from cesium carbonate, potassium carbonate, sodium carbonate, potassium phosphate, and DBU; The molar ratio of the compound of formula A7-P-intermediate 1 to the base is preferably 1:(0.7~6), including but not limited to 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The temperature of the methylation reaction can be a conventional reaction temperature for this type of reaction, such as room temperature; The progress of the methylation reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7-PM-intermediate 1. The preferred method for preparing the compound of formula A7-PM-intermediate 3 or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a palladium catalyst, a ligand, and a base, the compound of formula A7-PM-intermediate 2 is coupled with the compound of formula Z3 to prepare the compound of formula A7-PM-intermediate 3; The molar ratio of the compound of formula A7-PM-intermediate 2 to the compound of formula Z3 is preferably 1:(0.9~5), including but not limited to 1:0.9, 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2, 1:3, 1:4, and 1:5; The solvent is preferably one or more of 1,4-dioxane, DMSO, DMF, tetrahydrofuran, toluene, acetonitrile, and water; The base is selected from one or more of dipotassium hydrogen phosphate, cesium carbonate, potassium carbonate, sodium carbonate, and triethylamine; The molar ratio of the compound of formula A7-PM-intermediate 2 to the base is preferably 1:(1~6), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The palladium catalyst is preferably palladium acetate; The preferred molar ratio of the compound of formula A7-PM-intermediate 2 to the palladium catalyst is 1:(0.005~0.5), including but not limited to 1:0.005, 1:0.01, 1:0.01, 1:0.05, 1:0.1, 1:0.2, 1:0.3, 1:0.4, and 1:0.5. The ligand is preferably triphenylphosphine; The preferred molar ratio of the compound of formula A7-PM-intermediate 2 to the ligand is 1:(0.005~0.5), including but not limited to 1:0.005, 1:0.01, 1:0.05, 1:0.1, 1:0.2, 1:0.3, 1:0.4, and 1:0.5. The temperature of the coupling reaction can be a conventional reaction temperature for this type of reaction. The temperature of the coupling reaction can be 40℃~100℃, including but not limited to 40℃, 50℃, 60℃, 70℃, 80℃, 90℃, and 100℃.
[0160] The process of the coupling reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7-PM-intermediate 2.
[0161] The preferred method for preparing the compound of formula A7-PM or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7-PM-intermediate 3 or its pharmacologically acceptable salt is subjected to a hydrolysis reaction to prepare the compound of formula A7-PM or its pharmacologically acceptable salt; The solvent is preferably one or more selected from tetrahydrofuran, methanol, and ethanol. The alkali is preferably one or more selected from lithium hydroxide, sodium hydroxide, and potassium hydroxide; The molar ratio of the compound of formula A7-PM-intermediate 3 to the base is preferably 1:(1~8), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, and 1:8; The temperature of the hydrolysis reaction can be a conventional reaction temperature for this type of reaction, such as room temperature; The progress of the hydrolysis reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7-PM-intermediate 3.
[0162] In another aspect, the present invention also provides a method for preparing a compound of formula A7'-PM, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: A7'-P compound or its pharmacologically acceptable salt is prepared by contacting a halomethane with a nucleophilic substitution reaction to carry out a nucleophilic substitution reaction; The definitions of R2, R5~R7, m, R10~R12 and n are as described above.
[0163] In this invention, the conditions and operations in the nucleophilic substitution reaction in the above steps are all conventional conditions and operations in the art.
[0164] In another aspect, the present invention also provides a method for preparing a compound of formula A7'-PM, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: A compound of formula A7'-P or its pharmacologically acceptable salt is contacted with a carbonyl-containing compound to carry out a ring-closure reaction, thereby preparing a compound of formula A7'-P-intermediate 1 or its pharmacologically acceptable salt; The compound of formula A7'-P-intermediate 1 or its pharmacologically acceptable salt is contacted with a methylating agent to carry out a methylation reaction, thereby preparing compound of formula A7'-P-intermediate 2 or its pharmacologically acceptable salt; The compound of formula A7'-P-intermediate 2 or its pharmacologically acceptable salt is prepared by hydrolysis. The definitions of R2, R5~R7, m, R10~R12 and n are as described above.
[0165] In this invention, the conditions and operations in the cyclization reaction, methylation reaction and hydrolysis reaction in the above steps are all conventional conditions and operations in the art.
[0166] In another aspect, the present invention also provides a compound of formula A7-M, a compound of formula A7'-M, a compound of formula A7-PM, a compound of formula A7'-PM, an optical isomer thereof, or a pharmacologically acceptable salt thereof: The definitions of R1~R2, R5~R7, m, R10~R12 and n are as described above.
[0167] In some embodiments of the present invention, the compound of formula A7-M is selected from... , , or .
[0168] In some embodiments of the present invention, the compound of formula A7'-M is selected from... , , or .
[0169] In some embodiments of the present invention, the compound of formula A7-PM is selected from... or .
[0170] In some embodiments of the present invention, the compound of formula A7'-PM is selected from... or .
[0171] In another aspect, the present invention also provides a method for preparing a compound of formula AA7, a compound of formula AA7', a compound of formula AA7-P, a compound of formula AA7'-P, a compound of formula AA7-M, a compound of formula AA7'-M, a compound of formula AA7-PM, a compound of formula AA7'-PM, an optical isomer thereof, or a pharmacologically acceptable salt thereof, comprising the following steps: Compounds of formula A7, A7', A7-P, A7'-P, A7-M, A7'-M, A7-PM, or A7'-PM are prepared by subjecting compounds of formula A7, A7', A7-P, A7'-P, A7-M, A7'-M, A7-PM, or A7'-PM to hydroxyl protection reactions. The definitions of R1~R2, R5~R7, m, R10~R12, and n are as described above; R14 is -O-(S=O)2-R15, -OC(=O)R16, or -O-R17; R15 is selected from methyl or phenyl, wherein the methyl or phenyl group is optionally substituted by 1, 2 or 3 Rd; R16 is selected from methyl or phenyl, wherein the methyl or phenyl group is optionally substituted by 1, 2 or 3 Rd; R17 is selected from hydroxyl protecting groups; Each occurrence of Rd is independently selected from H, F, methyl, or nitro.
[0172] In some embodiments of the present invention, the hydroxyl protecting group is a group used in the field of organic chemistry to protect hydroxyl groups, for example, R17 may be TBS, MOM or THP.
[0173] In some embodiments of the present invention, R14 is preferably -O-TBS, -O-MOM, -OTs, -Oms, -OAc or -OBz.
[0174] In this invention, the conditions and operations in the hydroxyl protection reaction in the above steps are all conventional conditions and operations in the art.
[0175] In another aspect of the invention, the invention also provides a compound of formula AA7, a compound of formula AA7', a compound of formula AA7-P, a compound of formula AA7'-P, a compound of formula AA7-M, a compound of formula AA7'-M, a compound of formula AA7-PM, a compound of formula AA7'-PM, an optical isomer thereof, or a pharmacologically acceptable salt thereof: The definitions of R1~R2, R5~R7, m, R10~R12, n, and R14 are as described above; In some embodiments of the present invention, R14 is preferably -O-TBS, -O-MOM, -OTs, -Oms, -OAc or -OBz.
[0176] In another aspect of the invention, the invention also provides the use of compound Z4 in the preparation of compounds of formula A8, A8', A8-P, A8'-P, A8-M, A8'-M, A8-PM, A8'-PM, A9, A9', A9-P, A9'-P, A9-M, A9'-M, A9-PM, A9'-PM, their optical isomers, or their pharmacologically acceptable salts. , The definitions of R1~R2, R5~R7, m, R10~R12, and n are as described above; when When the dashed lines represent single bonds, Y is CH(R9), Z is CH2, and W is selected from N(R8); when When the dashed line indicates no protecting group, Y represents H, R8, or a hydroxyl protecting group, Z represents H, and W is selected from NH or O. R8 is selected from amino protecting groups, Ns, acrylonitrile, or 3-chloropropyl; R9 is selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl, or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy groups are optionally substituted with 1, 2, or 3 Rc groups; Each occurrence of Rc is independently selected from -H, -F, -Cl, -Br, -I, -OH, -NH2, -CH3, -CF3, -C2H5, -CN, -SF5, -CHO, -COOH, or -C(=O)NH2.
[0177] In some embodiments of the present invention, R9 is preferably -H, -F, -Cl, -Br, methyl, ethyl, or propyl.
[0178] In some embodiments of the present invention, the amine protecting group is a group used in the field of organic chemistry to protect amine groups, such as Boc.
[0179] In some embodiments of the present invention, the hydroxyl protecting group is a group used in the field of organic chemistry to protect hydroxyl groups, such as TBS, MOM or THP.
[0180] In some embodiments of the present invention, the compound of formula Z4 is selected from... or ; When R9 is not -H, the compound of formula Z4 is .
[0181] Furthermore, the compound of formula Z4-1 is selected from... , , , , , , or .
[0182] Furthermore, the compound of formula Z4-2 is selected from... or Preferred , , , , or .
[0183] In some embodiments of the present invention, the preparation of the compound of formula Z4-1 includes the following steps: Compound Z4a was subjected to an amino protection reaction with di-tert-butyl dicarbonate to prepare compound Z4b. Compound Z4b was subjected to a cyclooxygenation reaction with dichloroethylene to prepare compound Z4-1.
[0184] In this invention, the conditions and operations in the amine protection reaction and acetylation cyclization reaction in the above steps are all conventional conditions and operations in the art.
[0185] In another aspect, the present invention also provides a method for preparing a compound of formula A8, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Amination reaction of compound A7 or its pharmacologically acceptable salt with compound Z4 to prepare compound A8 or its pharmacologically acceptable salt; or Pathway 2: The compound of formula A6 undergoes a hydrolysis ring-opening reaction. After the hydrolysis ring-opening reaction is completed, the compound of formula Z4 is added to carry out a amide reaction to prepare the compound of formula A8 or its pharmacologically acceptable salt. The definitions of R1~R2, R5~R7, m, R13, W, Y and Z are as described above.
[0186] In this invention, the conditions and operations in the amination reaction in pathway 1 and the amination reaction and hydrolysis ring-opening reaction in pathway 2 are all conventional conditions and operations in the art.
[0187] The following conditions and operations are particularly preferred in this invention: In path 1, the preferred method for preparing the compound of formula A8 or its pharmacologically acceptable salt is as follows: in a solvent, the compound of formula A7 is contacted with the compound of formula Z4 to carry out an amination reaction to prepare the compound of formula A8 or its pharmacologically acceptable salt; The molar ratio of the compound of formula A7 to the compound of formula Z4 is preferably 1:(0.6~2), including but not limited to 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, and 1:2.
[0188] The molar ratio of the compound of formula A7 to the compound of formula Z4 is preferably 1:(1~6), including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:2, 1:3, 1:4, 1:5, and 1:6.
[0189] The solvent is preferably DMF. The amination reaction can also be carried out in the presence of a base. The base is preferably one or more selected from N,N-diisopropylethylamine, pyridine, sodium bicarbonate, sodium carbonate, and triethylamine. The molar ratio of the compound of formula A7 to the base is preferably 1:(0.1~6), including but not limited to 1:0.1, 1:0.5, 1:1, 1:1.5, 1:1.8, 1:2, 1:2.2, 1:2.5, 1:3, 1:4, 1:5, and 1:6. Further, when Z4 is Z4-1, the molar ratio of the compound of formula A7 to the base is preferably 1:(0.3~0.7), more preferably 1:0.5. Even further, the structure of Z4-1 is... .
[0190] Specifically, when Z4 is Z4-1, the amide reaction can be carried out without the addition of a base. Further, the Z4-1 structure is... .
[0191] The inventors have discovered that when Z4 is Z4-1, the yield of the reaction product can be increased when the amination reaction is carried out without the addition of a base. The inventors have also discovered that the yield of the reaction product can be increased when the amination reaction is carried out in the presence of a base and the molar ratio of the compound of formula A7 to the base is limited to 1:(0.3~0.7), preferably 1:0.5.
[0192] The temperature of the amide reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the amide reaction can be 10℃ to 30℃. Understandably, the temperature of the amide reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0193] The acetylation reaction can be monitored using conventional methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of compound A7. The preferred acetylation reaction time is 6 to 18 hours, for example, 12 hours or 16 hours.
[0194] In route 2, the conditions for the hydrolysis ring-opening reaction are preferably the same as those for the preparation of compound A7 from compound A6; the conditions for the amide reaction are preferably the same as those in route 1. Understandably, the product obtained from the hydrolysis ring-opening reaction in route 2 can be directly added to compound Z4 for amide reaction without separation, further shortening the synthesis time and saving costs.
[0195] In another aspect, the present invention also provides a method for preparing a compound of formula A8', its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Prepare compound A8' or its pharmacologically acceptable salt by acetylation reaction with compound Z4; or Pathway 2: The compound of formula A5 undergoes a hydrolysis ring-opening reaction. After the hydrolysis ring-opening reaction is completed, the compound of formula Z4 is added to carry out a amide reaction to prepare the compound of formula A8' or its pharmacologically acceptable salt. The definitions of R1~R2, R5~R7, m, R13, W, Y and Z are as described above.
[0196] In this invention, the conditions and operations in the amination reaction in pathway 1 and the amination reaction and hydrolysis ring-opening reaction in pathway 2 are all conventional conditions and operations in the art.
[0197] The following conditions and operations are particularly preferred in this invention: In path 1, the conditions for the acetylation reaction are preferably as described above. In route 2, the conditions for the hydrolysis ring-opening reaction are preferably the same as those for the preparation of compound A7' from compound A5; the conditions for the amide reaction are preferably the same as those in route 1. Understandably, the product obtained from the hydrolysis ring-opening reaction in route 2 can be directly added to compound Z4 for amide reaction without separation, further shortening the synthesis time and saving costs.
[0198] In another aspect, the present invention also provides a method for preparing a compound of formula A8-P, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Prepare compound A8-P or its pharmacologically acceptable salt by acetylation reaction with compound Z4; or Pathway 2: The compound of formula A6-P undergoes a hydrolysis ring-opening reaction. After the hydrolysis ring-opening reaction is completed, the compound of formula Z4 is added to carry out a amide reaction to prepare the compound of formula A8-P or its pharmacologically acceptable salt. The definitions of R2, R5~R7, m, R10~R12, n, R13, W, Y, and Z are as described above.
[0199] In this invention, the conditions and operations in the amination reaction in pathway 1 and the amination reaction and hydrolysis ring-opening reaction in pathway 2 are all conventional conditions and operations in the art.
[0200] The following conditions and operations are particularly preferred in this invention: In path 1, the conditions for the acetylation reaction are preferably as described above.
[0201] The following conditions and operations are particularly preferred in this invention: In route 1, the preferred method for preparing the compound of formula A8-P or its pharmacologically acceptable salt is as follows: in a solvent, the compound of formula A7-P is contacted with the compound of formula Z4 to undergo a amide reaction to prepare the compound of formula A8-P or its pharmacologically acceptable salt; The preferred molar ratio of the compound of formula A7-P to the compound of formula Z4 is 1:(1~6), including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:2, 1:3, 1:4, 1:5, and 1:6. The solvent is preferably DMF; The temperature of the amide reaction can be a conventional reaction temperature for this type of reaction, such as room temperature. The temperature of the amide reaction can be 10℃ to 30℃. It is understood that the temperature of the amide reaction includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃. The acetylation reaction can be monitored using conventional methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of the compound of formula A7-P. The preferred acetylation reaction time is 6 to 18 hours, for example, 12 hours or 16 hours.
[0202] In route 2, the conditions for the hydrolysis ring-opening reaction are preferably the same as those for the preparation of compound A7' from compound A5; the conditions for the amide reaction are preferably the same as those in route 1. Understandably, the product obtained from the hydrolysis ring-opening reaction in route 2 can be directly added to compound Z4 for amide reaction without separation, further shortening the synthesis time and saving costs.
[0203] In another aspect, the present invention also provides a method for preparing a compound of formula A8'-P, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Pathway 1: Prepare compound A8'-P or its pharmacologically acceptable salt by acetylation reaction with compound Z4; or Pathway 2: The compound of formula A5-P undergoes a hydrolysis ring-opening reaction. After the hydrolysis ring-opening reaction is completed, the compound of formula Z4 is added to carry out a amide reaction to prepare the compound of formula A8'-P or its pharmacologically acceptable salt. The definitions of R2, R5~R7, m, R10~R12, n, R13, W, Y, and Z are as described above.
[0204] In this invention, the conditions and operations in the amination reaction in pathway 1 and the amination reaction and hydrolysis ring-opening reaction in pathway 2 are all conventional conditions and operations in the art.
[0205] The following conditions and operations are particularly preferred in this invention: In path 1, the conditions for the acetylation reaction are preferably as described above. In route 2, the conditions for the hydrolysis ring-opening reaction are preferably the same as those for the preparation of compound A7' from compound A5; the conditions for the amide reaction are preferably the same as those in route 1. Understandably, the product obtained from the hydrolysis ring-opening reaction in route 2 can be directly added to compound Z4 for amide reaction without separation, further shortening the synthesis time and saving costs.
[0206] In another aspect, the present invention also provides a method for preparing a compound of formula A8-M, its optical isomer, or a pharmacologically acceptable salt thereof, characterized by comprising the following steps: Compound A7-M or its pharmacologically acceptable salt is prepared by acetylation with compound Z4; The definitions of R1~R2, R5~R7, m, W, Y and Z are as described above.
[0207] In this invention, the conditions and operations in the amination reaction of the above steps are all conventional conditions and operations in the art.
[0208] The following conditions and operations are particularly preferred in this invention: The conditions for the amination reaction are preferably as described above.
[0209] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the compound of formula A8-M or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7-M or its pharmacologically acceptable salt is contacted with the compound of formula Z4 to carry out an amination reaction, thereby preparing the compound of formula A8-M or its pharmacologically acceptable salt; The molar ratio of the compound of formula A7-M to the compound of formula Z4 is preferably 1:(1~6), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The solvent is preferably DMF; Preferably, the base is one or more selected from N,N-diisopropylethylamine, pyridine, and triethylamine; The molar ratio of the compound of formula A7-M to the base is preferably 1:(0.1~6), including but not limited to 1:0.1, 1:0.5, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The temperature of the acetylation reaction can be a conventional reaction temperature for this type of reaction, such as room temperature; The progress of the acetylation reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of compound A7-M.
[0210] In another aspect, the present invention also provides a method for preparing a compound of formula A8'-M, its optical isomer, or a pharmacologically acceptable salt thereof, characterized by comprising the following steps: Compound A7'-M or its pharmacologically acceptable salt is prepared by acetylation of compound Z4; The definitions of R1~R2, R5~R7, m, W, Y and Z are as described above.
[0211] In this invention, the conditions and operations in the amination reaction of the above steps are all conventional conditions and operations in the art.
[0212] The following conditions and operations are particularly preferred in this invention: The conditions for the amination reaction are preferably as described above.
[0213] In another aspect, the present invention also provides a method for preparing a compound of formula A8-PM, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Compound A7-PM or its pharmacologically acceptable salt is prepared by acetylation with compound Z4; The definitions of R2, R5~R7, m, R10~R12, n, W, Y and Z are as described above.
[0214] In this invention, the conditions and operations in the amination reaction of the above steps are all conventional conditions and operations in the art.
[0215] The following conditions and operations are particularly preferred in this invention: The conditions for the amination reaction are preferably as described above.
[0216] The following conditions and operations are particularly preferred in this invention: The preferred method for preparing the compound of formula A8-PM or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A7-PM or its pharmacologically acceptable salt is contacted with the compound of formula Z4 to carry out an amination reaction, thereby preparing the compound of formula A8-PM or its pharmacologically acceptable salt; The molar ratio of the compound of formula A7-PM to the compound of formula Z4 is preferably 1:(1~6), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The solvent is preferably DMF; Preferably, the base is one or more selected from N,N-diisopropylethylamine, pyridine, and triethylamine; The molar ratio of the compound of formula A7-PM to the base is preferably 1:(0.1~6), including but not limited to 1:0.1, 1:0.5, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6; The temperature of the acetylation reaction can be a conventional reaction temperature for this type of reaction, such as room temperature; The progress of the acetylation reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of the compound of formula A7-PM.
[0217] In another aspect, the present invention also provides a method for preparing a compound of formula A8'-PM, its optical isomer, or a pharmacologically acceptable salt thereof, comprising the following steps: Compound A7'-PM or its pharmacologically acceptable salt is prepared by acetylation of compound Z4; The definitions of R2, R5~R7, m, R10~R12, n, W, Y and Z are as described above.
[0218] In this invention, the conditions and operations in the amination reaction of the above steps are all conventional conditions and operations in the art.
[0219] The following conditions and operations are particularly preferred in this invention: The conditions for the amination reaction are preferably as described above.
[0220] In another aspect of the invention, the invention also provides a compound of formula A8, a compound of formula A8', a compound of formula A8-P, a compound of formula A8'-P, a compound of formula A8-M, a compound of formula A8'-M, a compound of formula A8-PM, a compound of formula A8'-PM, an optical isomer thereof, or a pharmacologically acceptable salt thereof: The definitions of R1~R2, R5~R7, m, R10~R12, n, W, Y and Z are as described above.
[0221] In some embodiments of the present invention, the compound of formula A8 is selected from... or .
[0222] Furthermore, the compound of formula A8-1 is selected from... , , , , , , , , , , or .
[0223] Furthermore, the compound of formula A8-2 is selected from... , , , or .
[0224] In some embodiments of the present invention, the compound of formula A8' is selected from... or .
[0225] Furthermore, the compound of formula A8'-1 is selected from... , , , , , , , , , , or .
[0226] Furthermore, the compound of formula A8'-2 is selected from... , , , or .
[0227] In some embodiments of the present invention, the A8-M compound is selected from... or .
[0228] Furthermore, the A8-M-1 compound is selected from... , , , , , , , , , , or .
[0229] Furthermore, the A8-M-2 compound is selected from... , , , or .
[0230] In some embodiments of the present invention, the compound of formula A8'-M is selected from... or .
[0231] Furthermore, the compound of formula A8'-M-1 is selected from... , , , , , , , , , , or .
[0232] Furthermore, the compound of formula A8'-M-2 is selected from... , , , or .
[0233] In some embodiments of the present invention, the A8-P compound is selected from... or .
[0234] Further, the A8-P-1 compound is preferably... , , , , , , or .
[0235] Furthermore, the A8-P-2 compound is selected from... , , , or .
[0236] In some embodiments of the present invention, the compound of formula A8'-P is selected from... or .
[0237] Furthermore, the compound of formula A8'-P-1 is selected from... , , , , , , or .
[0238] Furthermore, the compound of formula A8'-P-2 is selected from... , , , or .
[0239] In some embodiments of the present invention, the compound of formula A8-PM is selected from... or .
[0240] Furthermore, the compound of formula A8-PM-1 is selected from... , , , , , , or .
[0241] Furthermore, the compound of formula A8-PM-2 is selected from... , , , or .
[0242] In some embodiments of the present invention, the compound of formula A8'-PM is selected from... or .
[0243] Furthermore, the compound of formula A8'-PM-1 is selected from... , , , , , , or .
[0244] Furthermore, the compound of formula A8'-PM-2 is selected from... , , , or .
[0245] In another aspect, the present invention also provides a method for preparing a compound of formula AA8, a compound of formula AA8', a compound of formula AA8-P, a compound of formula AA8'-P, a compound of formula AA8-M, a compound of formula AA8'-M, a compound of formula AA8-PM, a compound of formula AA8'-PM, an optical isomer thereof, or a pharmacologically acceptable salt thereof, comprising the following steps: Compounds of formula AA7, AA7', AA7-P, AA7'-P, AA7-M, AA7'-M, AA7-PM, AA7'-PM, their optical isomers, or their pharmacologically acceptable salts are prepared by acetylation with compound Z4 to prepare compounds of formula AA8, AA8', AA8-P, AA8'-P, AA8-M, AA8'-M, AA8-PM, AA8'-PM, their optical isomers, or their pharmacologically acceptable salts. The definitions of R1~R2, R5~R7, m, R10~R12, n, R14, W, Y, and Z are as described above; The conditions for the acetylation reaction are as described above.
[0246] In another aspect of the invention, the invention also provides a compound of formula AA8, a compound of formula AA8', a compound of formula AA8-P, a compound of formula AA8'-P, a compound of formula AA8-M, a compound of formula AA8'-M, a compound of formula AA8-PM, a compound of formula AA8'-PM, an optical isomer thereof, or a pharmacologically acceptable salt thereof: The definitions of R1~R2, R5~R7, m, R10~R12, n, R14, W, Y, and Z are as described above.
[0247] In another aspect, the present invention also provides a method for preparing a compound of formula A9 or its optical isomer, comprising the following steps: Pathway 1: Prepare compound A9 by cyclizing compound A8 or its pharmacologically acceptable salt; or Pathway 2: The compound of formula A6 is subjected to a hydrolysis ring-opening reaction. After the hydrolysis ring-opening reaction is completed, the compound of formula Z4 is added to carry out a amide reaction. After the amide reaction is completed, a cyclization reaction is carried out to prepare the compound of formula A9. The definitions of R1~R2, R5~R7, m, R13, W, Y and Z are as described above.
[0248] In this invention, the conditions and operations in the cyclization reaction in path 1, as well as the hydrolysis ring-opening reaction, acetylation reaction, and cyclization reaction in path 2, are all conventional conditions and operations in the art.
[0249] The following conditions and operations are particularly preferred in this invention: In path 1, the preferred method for preparing compound A9 is as follows: in a solvent, in the presence of a base, compound A8 is contacted with TsCl to carry out a cyclization reaction to prepare compound A9; Furthermore, the cyclization reaction is specifically divided into two steps: TsCl first undergoes a hydroxyl activation reaction with the compound of formula A8 to obtain an intermediate; then, the secondary amine within the intermediate molecule undergoes a nucleophilic substitution reaction with -OTs on the benzene ring, resulting in cyclization and yielding the compound of formula A9. The molar ratio of the compound of formula A8 to TsCl is preferably 1:(0.7~6), including but not limited to 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6.
[0250] The molar ratio of the compound of formula A8 to TsCl is preferably 1:(0.7~1.7), including but not limited to 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, and 1:1.7.
[0251] The molar ratio of the compound of formula A8 to TsCl is preferably 1:(1~6), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6.
[0252] The base is preferably an organic amine base. The organic amine base may be N,N-diisopropylethylamine.
[0253] The base is preferably one or more of N,N-diisopropylethylamine, pyridine, and triethylamine.
[0254] The molar ratio of the compound of formula A8 to the base is preferably 1:(1~6), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, and 1:6.
[0255] The solvent is preferably a nitrile solvent. The nitrile solvent may be acetonitrile.
[0256] The solvent is preferably one or more selected from THF, dichloromethane, acetonitrile, DMF and DMSO.
[0257] Furthermore, the contact method between the compound of formula A8 and TsCl is to slowly add an acetonitrile solution of TsCl to the reaction system.
[0258] The cyclization reaction temperature can be a conventional reaction temperature for this type of reaction, such as room temperature. The cyclization reaction temperature can be between 10℃ and 30℃. Understandably, the cyclization reaction temperature includes, but is not limited to, 10℃, 15℃, 20℃, 25℃, and 30℃.
[0259] The progress of the cyclization reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of the compound of formula A8.
[0260] In pathway 2, the conditions for the hydrolysis ring-opening reaction and the acetylation reaction are preferably as described above, and the conditions for the cyclization reaction are preferably as described above. It is understood that the product obtained from the hydrolysis ring-opening reaction in pathway 2 can be directly added to compound Z4 for acetylation without separation, and the product obtained from the acetylation reaction can continue to undergo cyclization without separation, further shortening the synthesis time and saving costs.
[0261] In another aspect, the present invention also provides a method for preparing a compound of formula A9' or its optical isomer, comprising the following steps: Pathway 1: Prepare compound A9' by cyclizing compound A8' or its pharmacologically acceptable salt; or Pathway 2: The compound of formula A5 is subjected to a hydrolysis ring-opening reaction. After the hydrolysis ring-opening reaction is completed, the compound of formula Z4 is added to carry out a amide reaction. After the amide reaction is completed, a cyclization reaction is carried out to prepare the compound of formula A9'. The definitions of R1~R2, R5~R7, m, R13, W, Y and Z are as described above.
[0262] In this invention, the conditions and operations in the cyclization reaction in path 1, as well as the hydrolysis ring-opening reaction, acetylation reaction, and cyclization reaction in path 2, are all conventional conditions and operations in the art. The following conditions and operations are particularly preferred in this invention: In path 1, the conditions for the cyclization reaction are preferably as described above. In Path 2, the conditions for the hydrolysis ring-opening reaction and the amide reaction are preferably as described above, and the conditions for the cyclization reaction are preferably as described above. It is understood that the product obtained from the hydrolysis ring-opening reaction in Path 2 can be directly added to compound Z4 for amide reaction without separation, and the product obtained from the amide reaction can continue to undergo cyclization without separation, further shortening the synthesis time and saving costs.
[0263] In some embodiments of the present invention, the compound of formula A8 is a compound of formula A8-1, and a compound of formula A9-1 is prepared; or the compound of formula A8 is a compound of formula A8-2, and a compound of formula A9-2 is prepared. Alternatively, the compound of formula A9-2 can be contacted with an ethyl derivative, and the compound of formula A9-1 can be prepared by nucleophilic substitution and reductive amination reactions to achieve cyclization. Alternatively, the compound of formula A8' may be a compound of formula A8'-1, and a compound of formula A9'-1 may be prepared; or the compound of formula A8' may be a compound of formula A8'-2, and a compound of formula A9'-2 may be prepared. Alternatively, the compound of formula A9'-2 can be contacted with an ethyl derivative, and the compound of formula A9'-1 can be prepared by nucleophilic substitution and reductive amination reactions to achieve cyclization. The definitions of W, Y, R8, and R9 are as described above.
[0264] In another aspect, the present invention also provides a method for preparing a compound of formula A9-P or its optical isomer, comprising the following steps: Pathway 1: Prepare compound A9-P by cyclizing compound A8-P or its pharmacologically acceptable salt; or Pathway 2: The compound of formula A6-P undergoes a hydrolysis ring-opening reaction. After the hydrolysis ring-opening reaction is completed, the compound of formula Z4 is added to carry out a amide reaction. After the amide reaction is completed, a cyclization reaction is carried out to prepare the compound of formula A9-P. The definitions of R2, R5~R7, m, R10~R12, n, W, Y, Z, and R13 are as described above.
[0265] In path 1, the conditions for the cyclization reaction are preferably as described above.
[0266] In path 1, the preferred method for preparing the compound of formula A9-P is as follows: in a solvent, in the presence of a base, the compound of formula A8-P is contacted with TsCl to carry out a cyclization reaction to prepare the compound of formula A9-P; Furthermore, the cyclization reaction is specifically divided into two steps: TsCl first undergoes a hydroxyl activation reaction with the compound of formula A8-P to obtain an intermediate; then, the secondary amine within the intermediate molecule undergoes a nucleophilic substitution reaction with -OTs on the benzene ring, resulting in cyclization and yielding the compound of formula A9-P. The molar ratio of the compound of formula A8-P to TsCl is preferably 1:(1~10), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10.
[0267] The base is preferably one or more of N,N-diisopropylethylamine, pyridine, and triethylamine.
[0268] The molar ratio of the compound of formula A8-P to the base is preferably 1:(2~12), including but not limited to 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, and 1:12.
[0269] The solvent is preferably one or more selected from THF, dichloromethane, acetonitrile, DMF and DMSO.
[0270] The cyclization reaction temperature can be a conventional reaction temperature for this type of reaction, such as room temperature. The progress of the cyclization reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of the compound of formula A8-P.
[0271] In Path 2, the conditions for the hydrolysis ring-opening reaction and the amide reaction are preferably as described above, and the conditions for the cyclization reaction are preferably as described above. It is understood that the product obtained from the hydrolysis ring-opening reaction in Path 2 can be directly added to compound Z4 for amide reaction without separation, and the product obtained from the amide reaction can continue to undergo cyclization without separation, further shortening the synthesis time and saving costs.
[0272] In another aspect, the present invention also provides a method for preparing a compound of formula A9'-P or its optical isomer, comprising the following steps: Pathway 1: Prepare compound A9'-P by cyclizing compound A8'-P or its pharmacologically acceptable salt; or Pathway 2: The compound of formula A5-P undergoes a hydrolysis ring-opening reaction. After the hydrolysis ring-opening reaction is completed, the compound of formula Z4 is added to carry out a amide reaction. After the amide reaction is completed, a cyclization reaction is carried out to prepare the compound of formula A9'-P. The definitions of R2, R5~R7, m, R10~R12, n, W, Y, Z, and R13 are as described above.
[0273] In path 1, the conditions for the cyclization reaction are preferably as described above. In pathway 2, the conditions for the hydrolysis ring-opening reaction and the acetylation reaction are preferably as described above, and the conditions for the cyclization reaction are preferably as described above. It is understood that the product obtained from the hydrolysis ring-opening reaction in pathway 2 can be directly added to compound Z4 for acetylation without separation, and the product obtained from the acetylation reaction can continue to undergo cyclization without separation, further shortening the synthesis time and saving costs.
[0274] In some embodiments of the present invention, the compound of formula A8-P is a compound of formula A8-P-1, and a compound of formula A9-P-1 is prepared; or the compound of formula A8-P is a compound of formula A8-P-2, and a compound of formula A9-P-2 is prepared. Alternatively, the compound of formula A9-P-2 can be contacted with an ethyl derivative, and cyclized via nucleophilic substitution and reductive amination to prepare the compound of formula A9-P-1; Alternatively, if the compound of formula A8'-P is a compound of formula A8'-P-1, a compound of formula A9'-P-1 can be prepared; or if the compound of formula A8'-P is a compound of formula A8'-P-2, a compound of formula A9'-P-2 can be prepared. Alternatively, the compound of formula A9'-P-2 can be contacted with an ethyl derivative, and cyclized via nucleophilic substitution and reductive amination to prepare the compound of formula A9'-P-1; The definitions of W, Y, R8, and R9 are as described above.
[0275] In another aspect, the present invention also provides a method for preparing a compound of formula A9-M or its optical isomer, comprising the following steps: Compound A9-M is prepared by cyclizing a compound of formula A8-M or its pharmacologically acceptable salt. The definitions of R1~R2, R5~R7, m, W, Y and Z are as described above.
[0276] The preferred method for preparing the compound of formula A9-M or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the compound of formula A8-M or its pharmacologically acceptable salt is contacted with TsCl to carry out a cyclization reaction, thereby preparing the compound of formula A9-M or its pharmacologically acceptable salt; Furthermore, the cyclization reaction is specifically divided into two steps: TsCl first undergoes a hydroxyl activation reaction with the compound of formula A8-M or its pharmacologically acceptable salt to obtain an intermediate; then, the secondary amine in the intermediate molecule undergoes a nucleophilic substitution reaction with -OTs on the benzene ring to close the ring and obtain the compound of formula A9-M or its pharmacologically acceptable salt. The molar ratio of the compound of formula A8-M to TsCl is preferably 1:(1~6), including but not limited to 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:4, 1:5, and 1:6; The solvent is preferably one or more selected from THF, dichloromethane, acetonitrile, DMF, and DMSO. Preferably, the base is one or more selected from N,N-diisopropylethylamine, pyridine, and triethylamine; The molar ratio of the compound of formula A8-M to the base is preferably 1:(1~6), including but not limited to 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:4, 1:5, and 1:6; The cyclization reaction temperature can be a conventional reaction temperature for this type of reaction, such as room temperature. The cyclization reaction can be monitored using conventional methods in the art (e.g., LC-MS, TLC, HPLC, NMR, or GC), with the reaction endpoint generally defined as the disappearance or cessation of the reaction of the compound of formula A8-M. In another aspect of the invention, a method for preparing a compound of formula A9'-M or its optical isomers is also provided, comprising the following steps: Compound A9'-M is prepared by cyclizing a compound of formula A8'-M or its pharmacologically acceptable salt. The definitions of R1~R2, R5~R7, m, W, Y and Z are as described above.
[0277] In some embodiments of the present invention, the compound of formula A8-M is a compound of formula A8-M-1, and a compound of formula A9-M-1 is prepared; or the compound of formula A8-M is a compound of formula A8-M-2, and a compound of formula A9-M-2 is prepared. Alternatively, the compound of formula A9-M-2 can be contacted with an ethyl derivative, and cyclized via nucleophilic substitution and reductive amination to prepare the compound of formula A9-M-1; Alternatively, if the compound of formula A8'-M is a compound of formula A8'-M-1, a compound of formula A9'-M-1 can be prepared; or if the compound of formula A8'-M is a compound of formula A8'-M-2, a compound of formula A9'-M-2 can be prepared. Alternatively, the compound of formula A9'-M-2 can be contacted with an ethyl derivative, and cyclized via nucleophilic substitution and reductive amination to prepare the compound of formula A9'-M-1; The definitions of W, Y, R8, and R9 are as described above.
[0278] In another aspect, the present invention also provides a method for preparing a compound of formula A9-PM or its optical isomer, comprising the following steps: Compound A9-PM was prepared by cyclizing compound A8-PM or its pharmacologically acceptable salt. The definitions of R2, R5~R7, m, R10~R12, n, W, Y and Z are as described above.
[0279] The preferred method for preparing the A9-PM compound or its pharmacologically acceptable salt is as follows: in a solvent, in the presence of a base, the A8-PM compound or its pharmacologically acceptable salt is contacted with TsCl to carry out a cyclization reaction, thereby preparing the A9-PM compound or its pharmacologically acceptable salt; Furthermore, the cyclization reaction is specifically divided into two steps: TsCl first undergoes a hydroxyl activation reaction with the compound of formula A8-PM or its pharmacologically acceptable salt to obtain an intermediate; then, the secondary amine in the intermediate molecule undergoes a nucleophilic substitution reaction with -OTs on the benzene ring to close the ring and obtain the compound of formula A9-PM or its pharmacologically acceptable salt. The preferred molar ratio of the compound of formula A8-PM to TsCl is 1:(1~10), including but not limited to 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10. The solvent is preferably one or more selected from THF, dichloromethane, acetonitrile, DMF, and DMSO. Preferably, the base is one or more selected from N,N-diisopropylethylamine, pyridine, and triethylamine; The molar ratio of the compound of formula A8-PM to the base is preferably 1:(1~12), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, and 1:12; The cyclization reaction temperature can be a conventional reaction temperature for this type of reaction, such as room temperature. The progress of the cyclization reaction can be monitored using conventional monitoring methods in the art (e.g., LC-MS, TLC, HPLC, NMR or GC), and the reaction endpoint is generally defined as the disappearance or cessation of the reaction of the compound of formula A8-PM.
[0280] In another aspect, the present invention also provides a method for preparing a compound of formula A9'-PM or its optical isomer, comprising the following steps: Compound A9'-PM was prepared by cyclizing a compound of formula A8'-PM or its pharmacologically acceptable salt. The definitions of R2, R5~R7, m, R10~R12, n, W, Y and Z are as described above.
[0281] In some embodiments of the present invention, the compound of formula A8-PM is a compound of formula A8-PM-1, and a compound of formula A9-PM-1 is prepared; or the compound of formula A8-M is a compound of formula A8-PM-2, and a compound of formula A9-PM-2 is prepared. Alternatively, the compound of formula A9-PM-2 can be contacted with an ethyl derivative, and the compound of formula A9-PM-1 can be prepared by nucleophilic substitution and reductive amination reactions to achieve cyclization. Alternatively, if the compound of formula A8'-PM is a compound of formula A8'-PM-1, a compound of formula A9'-PM-1 may be prepared; or if the compound of formula A8'-PM is a compound of formula A8'-PM-2, a compound of formula A9'-PM-2 may be prepared. Alternatively, the compound of formula A9'-PM-2 can be contacted with an ethyl derivative, and cyclized via nucleophilic substitution and reductive amination to prepare the compound of formula A9'-PM-1; The definitions of W, Y, R8, and R9 are as described above.
[0282] In another aspect, the present invention also provides a method for preparing compounds of formula A9, A9', A9-P, A9'-P, A9-M, A9'-M, A9-PM, A9'-PM, or optical isomers thereof, comprising the following steps: Compound AA8 is subjected to a dehydroxylation protection reaction to prepare compound A8, and then compound A8 is subjected to a cyclization reaction to prepare compound A9; wherein, when R14 is -O-(S=O)2-R15, the method for preparing compound A9 does not involve the step of preparing compound A8 from compound AA8, but directly performs a cyclization reaction on compound AA8 to prepare compound A9; Compound AA8' is subjected to a dehydroxylation protection reaction to prepare compound A8', and then compound A8' is subjected to a cyclization reaction to prepare compound A9'; wherein, when R14 is -O-(S=O)2-R15, the method for preparing compound A9' does not involve the step of preparing compound A8' from compound AA8', but directly cyclizes compound AA8' to prepare compound A9'. Compound AA8-P is prepared by dehydroxylation protection, followed by cyclization to prepare compound A9-P. When R14 is -O-(S=O)2-R15, the preparation method of compound A9-P skips the step of preparing compound A8-P from compound AA8-P, and directly proceeds to cyclization to prepare compound A9-P. Compound A8'-P is prepared by dehydroxylation of compound AA8'-P, followed by cyclization of compound A8'-P to prepare compound A9'-P. When R14 is -O-(S=O)2-R15, the method for preparing compound A9'-P bypasses the step of preparing compound A8'-P from compound AA8'-P, and directly proceeds to cyclization of compound AA8'-P to prepare compound A9'-P. Compound AA8-M is prepared by dehydroxylation protection, followed by cyclization to prepare compound A9-M. When R14 is -O-(S=O)2-R15, the preparation method of compound A9-M bypasses the step of preparing compound A8-M from compound AA8-M, and directly proceeds to cyclization to prepare compound A9-M. Compound A8'-M is prepared by dehydroxylation protection of compound AA8'-M, followed by cyclization of compound A8'-M to prepare compound A9'-M; wherein, when R14 is -O-(S=O)2-R15, the method for preparing compound A9'-M does not involve the step of preparing compound A8'-M from compound AA8'-M, but directly cyclizes compound AA8'-M to prepare compound A9'-M. The AA8-PM compound is subjected to a dehydroxylation protection reaction to prepare the A8-PM compound, and then the A8-PM compound is subjected to a cyclization reaction to prepare the A9-PM compound; wherein, when R14 is -O-(S=O)2-R15, the preparation method of the A9-PM compound skips the step of preparing the A8-PM compound from the AA8-P compound, and directly performs a cyclization reaction on the AA8-PM compound to prepare the A9-PM compound; The compound of formula AA8'-PM is subjected to a dehydroxylation protection reaction to prepare compound A8'-PM, and then the compound of formula A8'-PM is subjected to a cyclization reaction to prepare compound A9'-PM; wherein, when R14 is -O-(S=O)2-R15, the method for preparing compound A9'-PM does not involve the step of preparing compound A8'-PM from compound AA8'-P, but directly cyclizes compound AA8'-PM to prepare compound A9'-PM; The definitions of R1~R2, R5~R7, m, R10~R12, n, R14, R15, W, Y and Z are as described above.
[0283] Definitions and Explanations Unless otherwise stated, the following terms and phrases as used herein are intended to have the following meanings. A particular term or phrase should not be considered uncertain or unclear unless specifically defined, but should be understood in its ordinary sense. When a trade name appears in this document, it is intended to refer to the corresponding product or its active ingredient.
[0284] The term "pharmacologically acceptable" as used herein refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0285] The term "pharmacologically acceptable salt" refers to a salt of the compounds of this invention, prepared by reacting a compound with a specific substituent, as discovered in this invention, with a relatively non-toxic acid or base. When the compounds of this invention contain relatively acidic functional groups, base addition salts can be obtained by contacting a neutral form of such compound with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmacologically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine, or magnesium salts, or similar salts. When the compounds of this invention contain relatively basic functional groups, acid addition salts can be obtained by contacting a neutral form of such compound with a sufficient amount of acid in a solution or a suitable inert solvent. Examples of pharmacologically acceptable acid addition salts include inorganic acid salts, such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, trifluoroacetic acid, maleic acid, malonic acid, benzoic acid, succinic acid, octanoic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; and also include salts of amino acids (such as arginine), and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic functional groups, and thus can be converted into either a base or an acid addition salt.
[0286] The pharmacologically acceptable salts of the present invention can be synthesized from parent compounds containing acid radicals or bases by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of a suitable base or acid in water or an organic solvent or a mixture of both.
[0287] As used herein, the term "and / or" encompasses any one of two or more of the related listed items, as well as any and all combinations of the related listed items. These arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. For example, "A and / or B" includes three parallel options: A, B, and "a combination of A and B".
[0288] In this document, unless otherwise stated, "one or more" means any one of the listed items or any combination of the listed items. Similarly, "one or more" and other instances of "one or more" shall be understood in the same way unless otherwise stated.
[0289] In this document, terms such as "further," "even more," "especially," "for example," "like," "example," and "exemplary" are used for descriptive purposes to indicate a relationship in the coverage of different technical solutions presented earlier and later. However, they should not be construed as limitations on the preceding technical solution or as restrictions on the scope of protection of this document. Unless otherwise specified, in this document, A (e.g., B) indicates that B is a non-limiting example of A, and it can be understood that A is not limited to B.
[0290] In this article, "optionally," "optional," and "optional" refer to options that are optional, meaning they can be chosen from either "with" or "without." If a technical solution has multiple "options," and unless otherwise specified, and there are no contradictions or mutual constraints, each "option" is independent.
[0291] In this document, the terms "first aspect," "second aspect," "third aspect," and "fourth aspect," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or quantity, nor should they be construed as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first," "second," "third," and "fourth" serve only as a non-exhaustive enumeration and should be understood as not constituting a closed limitation on quantity.
[0292] In this article, the technical features described in an open-ended manner include both closed technical solutions composed of the listed features and open technical solutions that include the listed features.
[0293] In this document, when referring to numerical intervals (i.e., numerical ranges), unless otherwise specified, the distribution of selectable values within a numerical interval is considered continuous, and includes the two endpoints (i.e., the minimum and maximum values) of the numerical interval, as well as every value between these two endpoints. Unless otherwise specified, when a numerical interval refers only to integers within that interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints, which is equivalent to directly listing every integer. When multiple numerical ranges are provided to describe features or characteristics, these numerical ranges can be merged. In other words, unless otherwise specified, the numerical ranges disclosed in this document should be understood to include any and all subranges included therein. The "numerical value" in the numerical interval can be any quantitative value, such as a number, percentage, ratio, etc. The term "numerical interval" can be broadly included to include numerical interval types such as percentage intervals, ratio intervals, and proportion intervals.
[0294] In this document, the terms "room temperature" or "normal temperature" generally refer to 4°C to 35°C, for example, 20°C ± 5°C. In some embodiments of this document, "room temperature" or "normal temperature" refers to 10°C to 30°C. In some embodiments of this document, "room temperature" or "normal temperature" refers to 20°C to 30°C.
[0295] In this paper, where the method involves multiple steps, unless otherwise explicitly stated herein, the execution of these steps is not strictly limited in order and can be performed in any order other than that described. Moreover, any step may include multiple sub-steps or multiple stages, which are not necessarily completed at the same time, but can be executed at different times, and their execution order is not necessarily sequential, but can be performed alternately or simultaneously with other steps or parts of the sub-steps or stages of other steps.
[0296] The compounds of this invention can exist in specific geometric or stereoisomeric forms. This invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof, as well as other mixtures, such as mixtures enriched with enantiomers or diastereomers, all of which are within the scope of this invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are included within the scope of this invention.
[0297] Unless otherwise stated, the terms "tautomer" or "tautomer form" refer to isomers of different functional groups in dynamic equilibrium at room temperature, capable of rapidly interconverting into each other. If tautomerization is possible (e.g., in solution), chemical equilibrium of the tautomer can be achieved. For example, proton tautomers (also called prototropic tautomers) involve interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers involve interconversions involving the rearrangement of some bonding electrons. A specific example of keto-enol tautomerization is the interconversion between the tautomers pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
[0298] The compounds of this invention may contain non-natural proportions of atomic isotopes on one or more of the atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes such as tritium (3H), iodine-125 (125I), or C-14 (14C). As another example, deuterium may be used to replace hydrogen to form deuterated drugs. The bond between deuterium and carbon is stronger than that between ordinary hydrogen and carbon. Compared to undeuterated drugs, deuterated drugs have advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged biological half-life. All variations in the isotopic composition of the compounds of this invention, regardless of radioactivity, are included within the scope of this invention.
[0299] Those skilled in the art to which this invention pertains will understand that some compounds may contain one or more chiral centers, and thus have two or more stereoisomers. Therefore, the compounds of this invention may exist as a single stereoisomer (e.g., enantiomer, diastereomer) and mixtures thereof in any proportion, such as racemates, and, where appropriate, as tautomers and geometric isomers.
[0300] As used in this article, "stereoisomer" refers to compounds that have the same chemical composition but differ in the spatial arrangement of atoms or groups. Stereoisomers include enantiomers, diastereomers, and conformational isomers.
[0301] The term "enantiomer" as used in this article refers to two stereoisomers of a compound that are non-overlapping mirror images of each other.
[0302] As used herein, the term "diastereomer" refers to a stereoisomer that has two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers possess different physical properties, such as melting point, boiling point, spectral properties, or biological activity. Mixtures of diastereomers can be separated using high-resolution analytical methods such as electrophoresis and chromatography such as HPLC.
[0303] As used in this article, "stereoisomer" refers to compounds that have the same chemical composition but differ in the spatial arrangement of atoms or groups. Stereoisomers include enantiomers, diastereomers, and conformational isomers.
[0304] The term "enantiomer" as used in this article refers to two stereoisomers of a compound that are non-overlapping mirror images of each other.
[0305] As used herein, the term "diastereomer" refers to a stereoisomer that has two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers possess different physical properties, such as melting point, boiling point, spectral properties, or biological activity. Mixtures of diastereomers can be separated using high-resolution analytical methods such as electrophoresis and chromatography such as HPLC.
[0306] The term "cis-trans isomers" as used in this article refers to molecules with the same molecular formula and chemical bonds that are arranged in different configurations. Cis isomers are molecules with two identical atoms or groups on the same side of the double bond, while trans isomers are molecules with two identical atoms or groups on opposite sides of the double bond.
[0307] Many organic compounds exist in an optically active form, meaning they possess the ability to rotate the plane of polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration of the molecule with respect to its chiral center. The prefixes d and l, or (+) and (-), are used to indicate that the compound rotates the plane of polarized light, where (-) or l indicates that the compound is levorotatory. Compounds with the prefix (+) or d are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers can also be called enantiomers, and mixtures of such isomers are generally called enantiomeric mixtures. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur in chemical reactions or methods where there is no stereoselectivity or stereospecificity. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two optically inactive enantiomers. This invention includes all such possible isomers, including racemic mixtures, optically pure forms, and intermediate mixtures. If the compound contains a double bond, the substituent can be of E or Z configuration. If the compound contains a disubstituted cyclic hydrocarbon group, the cyclic hydrocarbon substituent can have a cis- or trans-configuration. That is, the compounds of this invention include, but are not limited to, cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof and other mixtures. The compounds of this invention containing asymmetric carbon atoms can be isolated in optically active pure form or in the form of a mixture of two or more isomers. The optically active pure form can be resolved from a mixture of two or more isomers or synthesized using chiral starting materials or chiral reagents.
[0308] When the bonds to chiral carbon in the formula of this invention are depicted as a straight line ( When referring to this formula, it should be understood that enantiomerically pure compounds and mixtures based on the (R) and (S) configurations of chiral carbon are included within its scope. Unless otherwise stated, wedge-shaped solid lines ( ) and wedge-shaped dashed key ( The absolute configuration of a solid center is represented by a straight solid line key ( ). ) and straight dashed key ( ) indicates the relative configuration of the center of the solid.
[0309] Racemic mixtures can be used in their original form or separated into individual isomers. Separation yields stereochemically pure compounds or mixtures enriched with one or more isomers. Methods for isomer separation are well-known, including physical methods such as chromatography using chiral adsorbents. Chiral isomers can be prepared from chiral precursors. Alternatively, a single isomer can be chemically separated from a mixture by forming a diastereomeric salt with a chiral acid (e.g., 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.). The salt is then fractionally crystallized, and one or both of the separated bases are released. Optionally, this process is repeated to obtain one or two isomers that substantially do not contain the other isomer, i.e., the desired stereoisomers with an optical purity of, for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% by weight. Alternatively, as is well known to those skilled in the art to which this invention pertains, the racemic compound can be covalently attached to a chiral compound (auxiliary compound) to obtain the diastereomeric isomer.
[0310] As used herein, the terms "tautomer" or "tautomer form" refer to structural isomers of different energies that can be interconverted via low-energy barriers. For example, proton tautomers (also known as proton transfer tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerization. Valence tautomers include interconversions via the recombination of some bonding electrons.
[0311] "Optional" or "optionally" means that the event or condition described below may occur but is not required to occur, and the description includes both the occurrence of said event or condition and the non-occurrence of said event or condition.
[0312] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, which may include deuterium and hydrogen variants, provided that the valence state of the particular atom is normal and the substituted compound is stable. The term "optionally substituted" means that it may or may not be substituted, unless otherwise specified, and the type and number of substituents may be arbitrary on the basis of chemical feasibility.
[0313] When any variable (e.g., R) appears more than once in the composition or structure of a compound, its definition is independent in each case. Therefore, for example, if a group is substituted by one, two, or three Rs, the group can optionally be substituted by up to three Rs, and each case has independent options for R. Furthermore, combinations of substituents and / or their variants are only permitted if such combinations produce a stable compound. For example, Can be selected , , and wait.
[0314] When one of the variables is selected as a single bond, it means that the two groups it connects to are directly connected, for example... When L2 represents a single bond, it indicates that the structure is actually... The hyphen ("-") not between two letters or symbols indicates the linking site of a substituent. For example, C1-6 alkyl carbonyl - refers to a C1-6 alkyl group linked to the rest of the molecule via a carbonyl group. However, when the linking site of a substituent is obvious to those skilled in the art, such as halogen substituents, the "-" may be omitted.
[0315] When the listed substituents do not specify which atom they are attached to the substituted group, such substituents can be bonded to any of their atoms. For example, a pyridinium substituent can be attached to the substituted group through any carbon atom on the pyridine ring.
[0316] When the listed linking groups do not specify their linking direction, the linking direction is arbitrary, for example, The linking group L is ,at this time The phenyl and cyclopentyl groups can be connected in the same direction as the reading order from left to right to form the structure. Alternatively, the phenyl and cyclopentyl groups can be connected in the reverse order of reading from left to right to form the phenyl group. The combination of the linking group, substituents, and / or their variants is permitted only if such a combination produces a stable compound.
[0317] Unless otherwise specified, the term "alkyl" means a saturated hydrocarbon group comprising a primary (normal) carbon atom, or a secondary carbon atom, or a tertiary carbon atom, or a quaternary carbon atom, or a combination thereof, which may represent a straight-chain and / or branched alkyl group, and may be monovalent (e.g., methyl), divalent (e.g., methylene), or polyvalent (e.g., methine). Unless otherwise specifically stated in the specification, alkyl groups may optionally be substituted.
[0318] Unless otherwise specified, the term "C1-6 alkyl" is used to denote a straight-chain or branched saturated hydrocarbon group consisting of 1 to 6 carbon atoms. The C1-6 alkyl group includes C1-5, C1-4, C2-6 alkyl groups, etc.; it can be monovalent (e.g., methyl), divalent (e.g., methylene), or polyvalent (e.g., methine). Examples of C1-6 alkyl groups include, but are not limited to, methyl ("Me"), ethyl ("Et"), propyl such as n-propyl ("n-Pr") or isopropyl ("i-Pr"), butyl such as n-butyl ("n-Bu"), isobutyl ("i-Bu"), dibutyl ("s-Bu") or tert-butyl ("t-Bu"), pentyl, hexyl, methylene, 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, etc.
[0319] Unless otherwise specified, the term "C1-6 alkoxy" refers to alkyl groups comprising 1 to 6 carbon atoms that are attached to the remainder of a molecule by an oxygen atom. C1-6 alkoxy groups include C1-4, C1-3, C1-2, C2-6, C2-4, C6, C5, C4, and C3 alkoxy groups. Examples of C1-6 alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy, and t-butoxy), pentoxy (including n-pentoxy, isopentoxy, and neopentoxy), hexoxy, methyleneoxy, ethoxy, propoxy, butoxy, and pentyrooxy groups.
[0320] Unless otherwise specified, the term "amine" can be monovalent. divalent Or multiple prices .
[0321] Unless otherwise specified, the term "alkylamine" refers to an alkyl group attached to the remainder of a molecule by an amino group as defined above, wherein "alkyl" in "alkyl group" is defined as described above. Unless specifically stated otherwise in the specification, the alkylamine group may optionally be substituted.
[0322] Unless otherwise specified, the term "alkylthio" refers to an alkyl group attached to the remainder of the molecule by a sulfur atom, wherein the "alkyl" in "alkyl group" is defined as described above. Unless specifically stated otherwise in the specification, the alkylthio group may optionally be substituted.
[0323] Those skilled in the art to which this invention pertains will understand that some compounds of formula (I) may contain one or more chiral centers, and thus have two or more stereoisomers. Therefore, the compounds of this invention may exist as a single stereoisomer (e.g., enantiomer, diastereomer) and mixtures thereof in any proportion, such as racemates, and, where appropriate, as tautomers and geometric isomers.
[0324] As used in this article, "stereoisomer" refers to compounds that have the same chemical composition but differ in the spatial arrangement of atoms or groups. Stereoisomers include enantiomers, diastereomers, and conformational isomers.
[0325] As used in this article, "optical isomers" refers to molecules with different spatial arrangements, each exhibiting different optical rotations for plane-polarized light. Optical isomers typically refer to enantiomers, meaning they are mirror images of each other. They have identical chemical structures but exhibit different directions of optical rotation due to their different spatial arrangements.
[0326] The term "enantiomer" as used in this article refers to two stereoisomers of a compound that are non-overlapping mirror images of each other.
[0327] As used herein, the term "diastereomer" refers to a stereoisomer that has two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers possess different physical properties, such as melting point, boiling point, spectral properties, or biological activity. Mixtures of diastereomers can be separated using high-resolution analytical methods such as electrophoresis and chromatography such as HPLC.
[0328] The term "cis-trans isomers" as used in this article refers to molecules with the same molecular formula and chemical bonds that are arranged in different configurations. Cis isomers are molecules with two identical atoms or groups on the same side of the double bond, while trans isomers are molecules with two identical atoms or groups on opposite sides of the double bond.
[0329] Many organic compounds exist in an optically active form, meaning they possess the ability to rotate the plane of polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration of the molecule with respect to its chiral center. The prefixes d and l, or (+) and (-), are used to indicate that the compound rotates the plane of polarized light, where (-) or l indicates that the compound is levorotatory. Compounds with the prefix (+) or d are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers can also be called enantiomers, and mixtures of such isomers are generally called enantiomeric mixtures. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur in chemical reactions or methods where there is no stereoselectivity or stereospecificity. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two optically inactive enantiomers. This invention includes all such possible isomers, including racemic mixtures, optically pure forms, and intermediate mixtures. If the compound contains a double bond, the substituent can be of E or Z configuration. If the compound contains a disubstituted cyclic hydrocarbon group, the cyclic hydrocarbon substituent can have a cis- or trans-configuration. That is, the compounds of this invention include, but are not limited to, cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof and other mixtures. The compounds of this invention containing asymmetric carbon atoms can be isolated in optically active pure form or in the form of a mixture of two or more isomers. The optically active pure form can be resolved from a mixture of two or more isomers or synthesized using chiral starting materials or chiral reagents.
[0330] When the bonds to chiral carbon in the formula of this invention are depicted as a straight line ( When referring to this formula, it should be understood that enantiomerically pure compounds and mixtures based on the (R) and (S) configurations of chiral carbon are included within its scope. Unless otherwise stated, wedge-shaped solid lines ( ) and wedge-shaped dashed key ( The absolute configuration of a solid center is represented by a straight solid line key ( ). ) and straight dashed key ( ) indicates the relative configuration of the center of the solid.
[0331] Racemic mixtures can be used in their original form or separated into individual isomers. Separation yields stereochemically pure compounds or mixtures enriched with one or more isomers. Methods for isomer separation are well-known, including physical methods such as chromatography using chiral adsorbents. Chiral isomers can be prepared from chiral precursors. Alternatively, a single isomer can be chemically separated from a mixture by forming a diastereomeric salt with a chiral acid (e.g., 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.). The salt is then fractionally crystallized, and one or both of the separated bases are released. Optionally, this process is repeated to obtain one or two isomers that substantially do not contain the other isomer, i.e., the desired stereoisomers with an optical purity of, for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% by weight. Alternatively, as is well known to those skilled in the art to which this invention pertains, the racemic compound can be covalently attached to a chiral compound (auxiliary compound) to obtain the diastereomeric isomer.
[0332] As used herein, the terms "tautomer" or "tautomer form" refer to structural isomers of different energies that can be interconverted via low-energy barriers. For example, proton tautomers (also known as proton transfer tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerization. Valence tautomers include interconversions via the recombination of some bonding electrons.
[0333] The present application will be further described in detail below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the present application. For experimental methods in the following embodiments where specific conditions are not specified, please refer to the guidelines given in this application, or follow experimental manuals or conventional conditions in the art, or follow the conditions recommended by the manufacturer, or refer to experimental methods known in the art.
[0334] In the specific embodiments described below, the measurement parameters of the raw material components may have slight deviations within the weighing accuracy range unless otherwise specified. For temperature and time parameters, acceptable deviations due to instrument testing accuracy or operational precision are permissible.
[0335] Undefined technical and scientific terms used herein have the meanings commonly understood by one of ordinary knowledge in the field to which this invention pertains. Implementation
[0336] The present application is described in detail below with reference to embodiments, but this does not imply any adverse limitations on the present application. The present application has been described in detail herein, and specific embodiments thereof have been disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present application without departing from the spirit and scope thereof.
[0337] Example 1
[0338] Step 1: Compound A1-1 (0.575 mol, 1.0 eq) was dissolved in a mixed solvent of 700 mL THF and 500 mL DCM. 1 mL DMF was added, and then oxalic acid (0.688 mol, 1.2 eq) was slowly added dropwise under an ice-water bath. The reaction was brought to room temperature and carried out for 3 hours. LC-MS showed that the starting material was completely converted. The solvent was removed by vacuum concentration, and 500 mL acetonitrile was added and distilled twice to obtain a concentrated oxalic acid solution. Add ethyl isocyanate (0.603 mol, 1.05 eq) and 600 ml acetonitrile to another three-necked flask, then add triethylamine (2.3 mol, 4.0 eq), stir until dissolved, and slowly add acetonitrile solution of chlorophenyl chloride (400 ml) under ice-water bath and nitrogen protection. Let the mixture react overnight at room temperature. LC-MS confirmed complete conversion of the starting material. Concentrate under reduced pressure to remove most of the solvent, then add 2-methyltetrahydrofuran (800 ml) and saturated brine (800 ml). Stir to separate the layers, and extract the aqueous phase twice with 2-methyltetrahydrofuran (700 ml × 2). Combine the organic layers and concentrate under reduced pressure to obtain compound A2-1, which can be used directly in the next step.
[0339] Step 2: Compound A2-1 was dissolved in a mixed solvent of 400 ml tetrahydrofuran and 400 ml water. Lithium hydroxide monohydrate (1.148 mol, 2.0 mol) was added, and the mixture was stirred at room temperature for 3 hours. LC-MS confirmed complete conversion of the starting material. Concentrated hydrochloric acid was added to adjust the pH of the reaction solution to approximately 9. The solution was concentrated under reduced pressure to remove most of the solvent. The resulting concentrate was stirred and beaten with 700 ml methyl tributyl ether for 1 hour, then filtered. The resulting solid was dissolved in a mixed solvent of 500 ml tetrahydrofuran and 200 ml water. Acetic acid was added to adjust the pH of the reaction solution to 2-3, and the solution was concentrated under reduced pressure to remove the solvent. The resulting concentrate was stirred and beaten with 700 ml water for 2 hours, then filtered. The filter cake was dried to obtain 127 g of compound A3-1, with a two-step yield of 75.4%. ¹H NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H), 8.61 (s, 1H).
[0340] Step 3: Compound A3-1 (0.275 mol) was dissolved in 800 mL of tetrahydrofuran, 1 mL of DMF was added, and then oxalic acid chloride (0.409 mol, 1.5 eq) was slowly added dropwise under an ice-water bath. The mixture was heated to room temperature and reacted for 3 hours. LC-MS showed that the starting material was completely converted. The solvent was removed by vacuum concentration, and 500 mL of tetrahydrofuran was added and distilled twice to obtain a concentrated oxalic acid chloride solution. Add 0.33 mol of 3-isopropyl-5-methylpyridin-4-amine (1.2 eq) and 200 ml of tetrahydrofuran to another reaction flask, and add DIPEA (0.55 mol, 2.0 eq) dropwise. Under ice-water bath and nitrogen protection, slowly add 150 ml of tetrahydrofuran solution of chloroacetyl chloride. Incubate overnight at room temperature. LC-MS confirms complete conversion of the starting material. Concentrate under reduced pressure to remove most of the solvent, then add 600 ml of ethyl acetate and 200 ml of water and stir to separate the layers. Extract the aqueous layer twice with ethyl acetate (300 ml × 2). Combine the organic layers, dry with anhydrous sodium sulfate, and concentrate under reduced pressure to obtain compound A4-1, which can be used directly in the next step.
[0341] Step 4: Compound A4-1 was dissolved in 500 ml DMF, and cesium carbonate (0.55 mol, 2.0 eq) was added. The mixture was stirred at room temperature for 4 hours. The reaction was confirmed by LC-MS to be complete conversion of the starting material. The solid was removed by diatomaceous earth filtration, and the mother liquor was collected. 800 ml ethyl acetate and 300 ml water were added and stirred to separate the layers. The aqueous layer was extracted twice with ethyl acetate (500 ml × 2). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 71 g of compound A5-1 (0.1825 mol). The two-step yield was 66.3%. 1H NMR (400 MHz, Chloroform-d) δ 8.48 (s, 1H), 8.35 (d, J = 5.0 Hz, 1H), 8.16 (s, 1H), 8.05 (s, 1H), 7.06-6.91 (m, 1H), 3.23-3.11 (m, 1H), 2.21 (s, 3H), 1.30-1.09 (m, 6H).
[0342] Step 5: Compound A5-1 (0.051 mol, 1.0 eq) and S-binaphthol phosphate (0.056 mol, 1.1 eq) were added to 200 ml of a 1 / 1 v / v mixture of acetone and water (Watson distilled water). The mixture was heated to 40°C and stirred for 24 hours. Explosion occurred, and stirring became impossible. Therefore, 400 ml of the 1 / 1 v / v mixture of acetone and water was added, and stirring continued for another 24 hours. The reaction solution changed from a white suspension to a yellow suspension. The solution was filtered, washed, and dried to obtain a filter cake. The filter cake was dissolved in 300 ml of dichloromethane. The pH of the solution was adjusted to about 10 by adding 30% sodium hydroxide solution under ice-water bath. The mixture was stirred and separated into layers. The aqueous layer was extracted twice with dichloromethane (200 ml × 2 times). The organic layers were combined and washed successively with water and saturated brine. After drying with anhydrous sodium sulfate, the mixture was concentrated under reduced pressure to obtain compound A6-1 (0.01798 mol), with a yield of 35% and a chiral purity of 98.8%.
[0343] Step 6: Compound A6-1 (0.051 mol, 1.0 eq) was dispersed in 2M hydrogen chloride / methanol (200 ml) and stirred at room temperature for 4 hours. LC-MS confirmed complete conversion of the starting material. The solvent was removed by concentration under reduced pressure, followed by vacuum drying to obtain compound A7-1 (0.047 mol), with a yield of 92.4%. ¹H NMR (400 MHz, Methanol-d⁴) δ 8.86 (d, J = 6.1 Hz, 1H), 8.77 (s, 1H), 8.11 (d, J = 6.1 Hz, 1H), 3.07 (m, 1H), 2.32 (s, 3H), 1.32 (dd, J = 19.5, 7.0 Hz, 6H).
[0344] Step 7: Compound A7-1 (0.022 mol, 1.0 eq) was dissolved in 100 mL of pyridine, and 20 mL of DMF and compound Z4-1-1 (0.037 mol, 1.68 eq) were added. The reaction was carried out overnight at room temperature. LC-MS confirmed complete conversion of the starting material. The solvent was removed by concentration under reduced pressure, and the mixture was extracted with 400 mL of ethyl acetate and 200 mL of water to separate the layers. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 11 g of brown solid. The 11 g brown solid was dispersed in 200 mL of 1% sodium hydroxide solution and stirred for 30 minutes. The mixture was filtered, and the mother liquor was collected. 100 mL of toluene was added to the mother liquor, and the mixture was stirred to separate the layers. The aqueous layer was collected, and the pH of the aqueous layer was adjusted to approximately 2 with 10% citric acid aqueous solution. The acidic aqueous layer was extracted with dichloromethane (400 mL × 2 times). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound A8-1-1 (0.01436 mol), with a yield of 65.3%. Synthesis of raw material Z4-1-1: Compound A (0.155 mol, 1.0 eq) was dissolved in a mixed solvent of methanol (160 ml) and water (160 ml). Then, under ice-water bath conditions, 50% sodium hydroxide solution was slowly added to adjust the pH of the reaction solution to approximately 10. Dibutyl dicarbonate (0.232 mol, 1.5 eq) was added, and 50% sodium hydroxide solution was added again to maintain the pH at approximately 10. The reaction was carried out at room temperature for 3 hours. 200 ml of water and 200 ml of petroleum ether were added to the reaction solution, and the mixture was stirred to separate the layers. The organic layer was discarded. The pH of the aqueous layer was adjusted to approximately 3 with saturated citric acid solution. The acidic aqueous layer was extracted twice with dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound B (white solid, 0.131 mol), with a yield of 84%. Add 400 ml of acetonitrile and DMF (0.1956 mol, 1.5 eq) to a three-necked flask. Slowly add sulfonium dichloroethylene (0.195 mol, 1.49 eq) under an ice-water bath and nitrogen protection. Stir at room temperature for 40 minutes. Dissolve compound B (0.131 mol, 1.0 eq) in 300 ml of acetonitrile and 21 g of pyridine. Slowly add this solution to the sulfonium dichloroethylene reaction mixture under an ice-water bath and nitrogen protection. React overnight at room temperature. Remove the solvent by vacuum concentration. Add 500 ml of ethyl acetate and 200 ml of water and stir to separate the layers. Extract the aqueous layer twice with ethyl acetate (500 ml × 2). Combine the organic layers, dry to anhydrous sodium sulfate, and concentrate under vacuum to obtain a solid. Stir the solid in 500 ml of n-heptane for 1 hour. Filter and dry to obtain compound Z4-1-1 (gray solid, 0.1147 mol), yield 87.8%. 1H NMR (400 MHz, Chloroform-d) δ 4.51- 4.16 (m, 3H), 4.11-3.93 (m, 1H), 3.42 (dd, J = 14.5, 6.2 Hz, 1H), 2.82-2.77 (m, 1H), 1.44 (s, 9H), 1.20 (d, J = 6.5 Hz, 3H).
[0345] Step 8: Compound A8-1-1 (0.032 mol, 1.0 eq) was dissolved in 100 mL of acetonitrile, and 11.1 mL of DIPEA (0.0637 mol, 2.0 eq) was added. A solution of TsCl (0.0382 mol, 1.2 eq) in acetonitrile (93 mL) was slowly added to the reaction mixture. The mixture was stirred at room temperature for 1 hour. LC-MS confirmed complete conversion of the starting material. The reaction mixture was concentrated under reduced pressure, dissolved in 100 mL of 2-methyltetrahydrofuran, washed twice with 100 mL of water, concentrated under reduced pressure, stirred and slurried in 100 mL of acetonitrile, filtered, and dried to obtain compound A9-1-1 (0.0216 mol), with a yield of 67% and a purity of 99.7%. 1H NMR (400 MHz, Chloroform-d) δ 8.61 (d, J = 4.9 Hz, 1H), 8.25 (d, J = 8.8 Hz, 1H), 8.13 (s, 1H), 7.18 (t, J = 4.9 Hz, 1H), 4.95 (d, J = 13.8 Hz, 1H), 4.68-4.26 (m, 1H), 3.89-3.33 (m, 2H), 3.22-2.81 (m, 2H), 2.52-2.35 (m, 1H), 1.96 (d, J = 15.7 Hz, 3H), 1.56 (d, J = 6.7 Hz, 3H), 1.52 (s, 9H), 1.26 -1.00 (m, 6H).
[0346] Example 2 Compound A5-1 (0.051 mol, 1.0 eq) and R-binaphthol phosphate (0.056 mol, 1.1 eq) were added to 720 ml of anisole and stirred at 10℃-20℃ for 3 h. Then, 36 ml of methanol was added and stirring continued for 1 h. A sample was taken (5 ml of the solid-liquid mixture was filtered, rinsed with 0.25 ml of anisole, and then rinsed with 1 ml of methyl ether; the solid and mother liquor were collected. The sampling and rinsing volumes can be scaled up proportionally). The ee value of the solid was determined; the ee value should be ≥92%. The conversion of the raw material A5-1 to ≤5% was determined by HPLC chirality of the mother liquor. If the reaction was not complete, samples were taken every 2 hours for monitoring until the reaction was complete. The filter cake was filtered and washed twice with a mixture of 440 ml anisole and 4 ml methanol, followed by two washes with 80 ml methyl tributyl ether. The resulting filter cake was then placed in a reaction vessel and 140 ml of n-heptane was added. The mixture was stirred for at least 2 hours, filtered, and washed twice with 30 ml of n-heptane. The filter cake was then dried. The filter cake was added to 200 ml of ethyl acetate at a controlled temperature of 10-20°C, and 15.6 g of triethylamine was added dropwise. The mixture was stirred for 1 hour until the reaction was complete. The filter cake was then washed twice with 45 ml of ethyl acetate. The resulting filtrate was washed twice with sodium chloride aqueous solution at a controlled temperature of 10-20°C. The organic phase was rotary evaporated to a certain proportion, and n-heptane was added. The mixture was cooled, filtered, dried, and discharged to obtain compound A6-1 (0.023 mol) with a yield of 45% and a chiral purity of 98%.
[0347] Example 3
[0348] Step 1: Compound A7-1 (28.75 mmol) was dissolved in tetrahydrofuran (100 mL), and N,N-diisopropylethylamine (172.50 mmol) was added. The mixture was cooled to 0°C. Triphosgene (31.63 mmol) was added in portions, and the mixture was brought to room temperature and stirred after the addition was complete. The reaction was monitored by sampling, and the reaction was confirmed to be complete. The reaction was quenched by adding ammonium chloride aqueous solution, and the mixture was stirred and clarified with ethyl acetate. The aqueous phase was extracted twice with EA, and the organic phases were combined, washed with saturated brine, dried, filtered, and concentrated to give A7-2-INT01 (11.5 g, 99% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.64 (d, J = 4.9 Hz, 1H), 8.23 (s, 1H), 7.19 (d, J = 4.9 Hz, 1H), 2.52 – 2.38(m, 1H), 1.95 (s, 3H), 1.16 (d, J = 6.7 Hz, 3H), 1.08 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 405.35.
[0349] Step 2: The A7-2-INT01 obtained in step 1 was dispersed in DMF (100 mL), and cesium carbonate (57.50 mmol) was added and stirred at room temperature. Iodomethane (86.25 mmol) was added, and the mixture was stirred at room temperature for 2 h. The reaction was monitored and samples were taken to ensure complete reaction. The aqueous phase was extracted twice with water / ethyl acetate (EA), and the organic phases were combined. The organic phase was washed three times with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain A7-2-INT02 (11 g, 91% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.62 (d, J = 4.9 Hz, 1H), 8.21 (s, 1H), 7.18 (d, J = 4.9 Hz, 1H), 3.71 (s, 3H), 2.46 – 2.52(m, 1H), 1.96 (s, 3H), 1.18 (d, J = 6.7 Hz, 3H), 1.07 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 419.36.
[0350] Step 3: A7-2-INT02 (9.54 mmol) was dissolved in tetrahydrofuran (40 mL), and then dissolved in an aqueous solution of sodium hydroxide (38.16 mmol). The mixture was stirred at room temperature for 8 h, and samples were taken for monitoring until the reaction was complete. The reaction was quenched with an aqueous solution of citric acid, and the pH of the aqueous solution was adjusted to a weakly alkaline state. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and ethyl acetate hydrochloride was added to the resulting organic phase. The mixture was concentrated to give A7-M-2 (4 g, 97% yield). MS (ESI) m / z (M+H)+ = 393.37.
[0351] Step 4: A7-M-2 (5.82 mmol) was dispersed in DMF (18.99 mL) solution, N,N-diisopropylethylamine (11.64 mmol) was added, and Z4-1-2 (11.64 mmol) was added. The mixture was stirred at room temperature for 12 h, and samples were taken for monitoring. The reaction was complete. Water was added, and the aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed three times with water. The organic phase was dried over anhydrous sodium sulfate, concentrated, and the resulting oil was directly added to the next step (3.0 g, yield 85%). MS (ESI) m / z (M+H)+ = 605.45. Synthesis of raw material Z4-1-2: Compound E was dispersed in DCM (140 mL), cooled in an ice bath, and DMF (0.1–2.0 eq) was added. SOCl2 (65.38 mmol, 4.75 mL) was added dropwise, and the reaction was carried out at room temperature for 5 h. A sample was taken for monitoring, and the reaction was considered complete. The reaction was quenched with water, and the organic phase was separated. The organic phase was washed with water, then with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give Z4-1-2 (9.0 g, 80% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 4.04–3.99 (m, 1H), 3.72–3.66 (m, 1H), 3.52–3.39 (m, 2H), 3.25–3.15 (m, 3H), 1.36 (s, 9H).
[0352] Step 5: A8-M-1-2 (4.95 mmol) was weighed and dissolved in THF (30 mL). N,N-diisopropylethylamine (7.43 mmol) and TsCl (5.95 mmol) were added, and the mixture was stirred at room temperature for 2 h. The reaction was monitored by sampling. Once complete, water was added, and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed twice with brine. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A9-M-1-2 (2.5 g, yield 83%). 1H NMR (400 MHz, Chloroform-d) δ 8.62 (d, J = 4.9 Hz, 1H), 8.19 (s, 1H), 7.17 (d, J = 4.8 Hz, 1H), 4.98 (d, J = 13.4 Hz, 1H), 4.23 (d, J = 32.5 Hz, 1H), 3.48 (s, 3H), 3.55-3.10 (m, 4H), 2.96-2.82 (m, 1H), 2.71 – 2.59 (m, 1H), 1.89 (s, 3H), 1.55 (s, 9H), 1.22 (d, J = 6.7 Hz, 3H), 1.18 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 587.50.
[0353] Step 6: A9-M-1-2 (0.34 mmol), Z3-2-2 compound (0.54 mmol), dipotassium hydrogen phosphate (1.7 mmol), palladium acetate, and triphenylphosphine, 2% each, were dispersed in 1,4-dioxane (4 mL) and water (2 mL). The mixture was purged with nitrogen three times and heated to 80 °C for 12 hours. After sampling and testing, the reaction was confirmed to be complete. The reaction solution was cooled to room temperature, and water and ethyl acetate (20 mL) were added. The aqueous phase was extracted twice with ethyl acetate, and the combined organic phases were used. The organic phase was washed with sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A9-PM-1-2 (0.2 g, yield 89%). 1H NMR (400 MHz, Chloroform-d) δ 8.60 (d, J = 4.9 Hz, 1H), 8.32 (s, 1H), 7.26 – 7.18 (m, 2H), 6.73 – 6.61 (m, 2H), 5.00 (d, J = 13.4 Hz, 1H), 4.37 – 4.20 (m, 1H), 3.58 – 3.46 (m, 4H), 3.42-3.30 (m, 2H), 3.28-3.15 (m, 1H), 2.99-2.87 (m, 1H), 2.83 – 2.70 (m, 1H), 1.92 (s, 3H), 1.55 (s, 9H), 1.23 (d, J = 6.7 Hz, 3H), 1.10 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 663.40.
[0354] Example 4
[0355] Step 1: A7-1 (2.57 mmol) was dispersed in DMF (10 mL) solution, N,N-diisopropylethylamine (5.14 mmol) was added, and Z4-1-2 (3.08 mmol) was added. The mixture was stirred at room temperature for 16 h, and samples were taken for monitoring. The reaction was complete. Water was added, and the aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed three times with water. The organic phase was dried over anhydrous sodium sulfate, concentrated, and the resulting oil was directly added to the next step (1.3 g, yield 86%). MS (ESI) m / z (M+H)+ = 591.56.
[0356] Step 2: Weigh out 0.34 mmol of A8-1-2 and dissolve it in 5 mL of THF. Add N,N-diisopropylethylamine (0.64 mmol) and TsCl (0.51 mmol) and stir at room temperature for 16 h. Monitor the reaction by taking a sample. Once the reaction is complete, add water and extract the aqueous phase twice with ethyl acetate. Combine the organic phases and wash the organic phase twice with brine. Dry the organic phase with anhydrous sodium sulfate, filter, concentrate, and perform column chromatography to obtain 0.19 g of A9-1-2 (98% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.60 (d, J = 4.9 Hz, 1H), 8.26 (s, 1H), 8.18 (s, 1H), 7.15 (d, J = 4.9 Hz, 1H), 5.00 (d, J = 13.6 Hz, 1H), 4.33 – 4.15 (m, 1H), 3.72 – 3.57 (m, 1H), 3.39 – 3.29 (m, 1H), 3.29 – 3.17 (m, 2H), 3.08 – 2.94 (m, 1H), 2.53 – 2.40 (m, 1H), 1.93 (s, 3H), 1.51 (s, 9H), 1.16 (d, J = 6.7 Hz, 3H), 1.10 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 573.57.
[0357] Step 3: A9-1-2 (1.7 mmol) was dispersed in DMF (15 mL), and cesium carbonate (5.2 mmol) was added and stirred at room temperature. Iodomethane (8.7 mmol) was added, and the mixture was stirred at room temperature for 2 h. The reaction was monitored and the sample was taken to ensure complete reaction. The aqueous phase was extracted twice with water / ethyl acetate (EA), and the organic phases were combined. The organic phase was washed three times with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain A9-M-1-2 (0.97 g, 95% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.62 (d, J = 4.9 Hz, 1H), 8.19 (s, 1H), 7.17 (d, J = 4.8 Hz, 1H), 4.98 (d, J = 13.4 Hz, 1H), 4.23 (d, J = 32.5 Hz, 1H), 3.48 (s, 3H), 3.55-3.10 (m, 4H), 2.96-2.82 (m, 1H), 2.71 – 2.59 (m, 1H), 1.89 (s, 3H), 1.55 (s, 9H), 1.22 (d, J = 6.7 Hz, 3H), 1.18 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 587.40.
[0358] Step 4: A9-M-1-2 (0.34 mmol), Z3-2-2 compound (0.54 mmol), dipotassium hydrogen phosphate (1.7 mmol), palladium acetate, and triphenylphosphine, 2% each, were dispersed in 1,4-dioxane (4 mL) and water (2 mL). The mixture was purged with nitrogen three times and heated to 80 °C for 12 hours. After sampling and confirming complete reaction, the reaction solution was cooled to room temperature, and water and ethyl acetate (20 mL) were added. The aqueous phase was extracted twice with ethyl acetate, and the combined organic phases were obtained. The organic phase was washed with sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A9-PM-1-2 (0.2 g, 89% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.60 (d, J = 4.9 Hz, 1H), 8.32 (s, 1H), 7.26 – 7.18 (m, 2H), 6.73 – 6.61 (m, 2H), 5.00 (d, J = 13.4 Hz, 1H), 4.37 – 4.20 (m, 1H), 3.58 – 3.46 (m, 4H), 3.42-3.30 (m, 2H), 3.28-3.15 (m, 1H), 2.99-2.87 (m, 1H), 2.83 – 2.70 (m, 1H), 1.92 (s, 3H), 1.55 (s, 9H), 1.23 (d, J = 6.7 Hz, 3H), 1.10 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 663.40.
[0359] Example 5
[0360] Step 1: A6-1 (3.4 mmol), compound Z3-2-2 (5.4 mmol), dipotassium hydrogen phosphate (17 mmol), palladium acetate, and triphenylphosphine, 2% each, were dispersed in 1,4-dioxane (40 mL) and water (20 mL). The mixture was purged with nitrogen three times and heated to 80 °C for 12 hours. After sampling and confirming complete reaction, the reaction solution was cooled to room temperature, and water and ethyl acetate (20 mL) were added. The aqueous phase was extracted twice with ethyl acetate, and the combined organic phases were obtained. The organic phase was washed with sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A6-P-4 (2.3 g, 92% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.54 (d, J = 5.0 Hz, 1H), 8.49 (s, 1H), 8.32 (s, 1H), 7.26 – 7.16 (m, 2H), 6.74 – 6.60 (m, 2H), 2.67 – 2.53 (m, 1H), 2.04 (s, 3H), 1.18 (d, J = 6.8 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H). MS (ESI) m / z (M+H)+= 465.20.
[0361] Step 2: A6-P-4 (20.0 mmol) was dispersed in hydrochloric acid-ethanol and stirred at room temperature for 5 h. The reaction was then analyzed, and the reaction was found to be complete. The solution was directly evaporated to dryness to obtain A7-P-4 (10 g, 95% yield). 1H NMR (400 MHz, DMSO-d 6) δ 8.73 (d, J = 5.8 Hz, 1H), 8.56 (s, 1H), 7.92 (t, J = 5.6 Hz, 1H), 7.26 – 7.14 (m, 1H), 6.73 (d, J = 8.3 Hz, 1H), 6.69 -6.58 (m, 3H), 2.89 -2.74 (m, 1H), 2.10 (d, J = 7.9 Hz, 3H), 1.27 (d, J = 7.0 Hz, 3H), 1.12 (dd, J = 11.0, 6.9 Hz, 3H). MS (ESI) m / z (M+H)+= 455.12.
[0362] Step 3: A7-P-4 (4.4 mmol) was dissolved in tetrahydrofuran (20 mL), and N,N-diisopropylethylamine (26.38 mmol) was added. The mixture was cooled to 0°C. Triphosgene (3.84 mmol) was added in portions, and the mixture was brought to room temperature and stirred after the addition was complete. The reaction was monitored by sampling, and the reaction was confirmed to be complete. The reaction was quenched by adding ammonium chloride aqueous solution, and the mixture was stirred and clarified with ethyl acetate. The aqueous phase was extracted twice with EA, and the organic phases were combined, washed with saturated brine, dried, filtered, concentrated, and subjected to column chromatography to obtain A7-PM-4-INT03 (2.10 g, 99% yield). MS (ESI) m / z (M+H)+ = 481.12.
[0363] Step 4: A7-PM-4-INT03 (4.4 mmol) was dispersed in DMF (20 mL), and cesium carbonate (13.19 mmol) was added and stirred at room temperature. Iodomethane (21.98 mmol) was added, and the mixture was stirred at room temperature for 3 h. The reaction was monitored and samples were taken to ensure complete reaction. The aqueous phase was extracted twice with water / ethyl acetate (EA), and the organic phases were combined. The organic phase was washed three times with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A7-PM-4-INT04 (1.9 g, 87% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.51 (dd, J = 4.9, 3.5 Hz, 1H), 8.25 (d, J = 1.1 Hz, 1H), 7.31 (td, J = 8.4, 6.6 Hz, 1H), 7.16 – 7.04 (m, 1H), 6.79 – 6.60 (m, 2H), 3.74 (s, 3H), 3.67 (d, J = 7.6 Hz, 3H), 2.66 – 2.50 (m, 1H), 1.95 (s, 3H), 1.20 (dd, J = 6.8, 5.0 Hz, 3H), 0.98 (dd, J = 13.7, 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 509.05.
[0364] Step 5: A7-PM-4-INT04 (2.0 mmol) was dissolved in a 48% aqueous solution of hydrogen bromide, heated to 100°C and refluxed overnight. The reaction was monitored by sampling until complete. The aqueous phase was adjusted to alkalinity with sodium carbonate solution, and the aqueous phase was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A7-PM-4-INT05 (0.9 g, 90% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.54 (d, J = 4.9 Hz, 1H), 8.32 (s, 1H), 8.18 (s, 1H), 7.25 – 7.13 (m, 2H), 6.65 (td, J = 8.4, 1.3 Hz, 2H), 3.74 (s, 3H), 2.50-2.62 (m, 1H), 1.99 (s, 3H), 1.18 (d, J = 6.7 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 495.15.
[0365] Step 6: A7-PM-4-INT05 (4.77 mmol) was dissolved in tetrahydrofuran (20 mL), and then dissolved in an aqueous solution of sodium hydroxide (19.08 mmol). The mixture was stirred at room temperature for 8 h, and samples were taken for monitoring until the reaction was complete. The reaction was quenched with an aqueous solution of citric acid, and the pH of the aqueous solution was adjusted to a slightly alkaline state. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and ethyl acetate hydrochloride was added to the resulting organic phase. The mixture was concentrated to give A7-PM-4 (1.9 g, 90% yield). MS (ESI) m / z (M+H)+ = 469.10.
[0366] Step 7: A7-PM-4 (1.89 mmol) was dispersed in DMF (10.0 mL) solution, N,N-diisopropylethylamine (4.74 mmol) was added, and Z4-1-2 (2.84 mmol) was added. The mixture was stirred at room temperature for 3 h, and samples were taken for monitoring. The reaction was complete. The reaction solution was directly added to the next step. N,N-diisopropylethylamine (18 mmol) and TsCl (12 mmol) were added to the reaction mixture, and the mixture was stirred at room temperature for 3 h. Samples were taken for monitoring. The reaction was complete. Water was added, and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed three times with brine. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A9-PM-1-2 (1.0 g, yield 80%). 1H NMR (400 MHz, Chloroform-d) δ 8.60 (d, J = 4.9 Hz, 1H), 8.32 (s, 1H), 7.26 – 7.18 (m, 2H), 6.73 – 6.61 (m, 2H), 5.00 (d, J = 13.4 Hz, 1H), 4.37 – 4.20 (m, 1H), 3.58 – 3.46 (m, 4H), 3.42-3.30 (m, 2H), 3.28-3.15 (m, 1H), 2.99-2.87 (m, 1H), 2.83 – 2.70 (m, 1H), 1.92 (s, 3H), 1.55 (s, 9H), 1.23 (d, J = 6.7 Hz, 3H), 1.10 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 663.40.
[0367] Example 6
[0368] Step 1: A6-1 (3.4 mmol), Z3-2-2 compound (5.4 mmol), dipotassium hydrogen phosphate (17 mmol), palladium acetate, and triphenylphosphine, 2% each, were dispersed in 1,4-dioxane (40 mL) and water (20 mL). The mixture was purged with nitrogen three times and heated to 80 °C for 12 hours. After sampling and confirming the reaction was complete, the reaction solution was cooled to room temperature, and water and ethyl acetate (20 mL) were added. The aqueous phase was extracted twice with ethyl acetate, and the combined organic phases were obtained. The organic phase was washed with sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A6-P-4 (2.3 g, 92% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.54 (d, J = 5.0 Hz, 1H), 8.49 (s, 1H), 8.32 (s, 1H), 7.26 – 7.16 (m, 2H), 6.74 – 6.60 (m, 2H), 2.67 – 2.53 (m, 1H), 2.04 (s, 3H), 1.18 (d, J = 6.8 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H). MS (ESI) m / z (M+H)+= 465.20.
[0369] Step 2: A6-P-4 (20.0 mmol) was dispersed in hydrochloric acid-ethanol and stirred at room temperature for 5 h. The reaction was then analyzed, and the reaction was found to be complete. A7-P-4 (10 g, 95% yield) was obtained by direct rotary evaporation. 1H NMR (400 MHz, DMSO-d 6) δ 8.73 (d, J = 5.8 Hz, 1H), 8.56 (s, 1H), 7.92 (t, J = 5.6 Hz, 1H), 7.26 – 7.14 (m, 1H), 6.73 (d, J = 8.3 Hz, 1H), 6.69 -6.58 (m, 3H), 2.89 -2.74 (m, 1H), 2.10 (d, J = 7.9 Hz, 3H), 1.27 (d, J = 7.0 Hz, 3H), 1.12 (dd, J = 11.0, 6.9 Hz, 3H). MS (ESI) m / z (M+H)+= 455.21.
[0370] Step 3: A7-P-4 (9.66 mmol) was dispersed in DMF (40.0 mL) solution, and Z4-1-2 (11.6 mmol) was added. The mixture was stirred at room temperature for 16 h, and samples were taken for monitoring. The reaction was complete. The reaction solution was directly added to the next step. N,N-diisopropylethylamine (91.7 mmol) and TsCl (62.8 mmol) were added to the reaction solution, and the mixture was stirred at room temperature for 2.5 h. Samples were taken for monitoring. The reaction was complete. Water was added, and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed three times with brine. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A9-P-1-5 (50% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.53 (d, J = 5.0 Hz, 1H), 8.38 - 8.22 (m, 2H), 7.23 - 7.09 (m, 2H), 6.73 - 6.54 (m, 2H), 4.99 (d, J = 16.0 Hz, 1H), 4.34 – 4.14(m, 1H), 3.78 -3.60 (m, 1H), 3.44 – 3.17 (m, 3H), 3.05 (t, J = 11.2 Hz, 1H), 2.67 – 2.45 (m, 1H), 1.94 (s, 3H), 1.51 (s, 8H), 1.16 (d, J = 6.7 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 649.20.
[0371] Step 4: A9-P-1-5 (1.5 mmol) was dispersed in DMF (10 mL), and cesium carbonate (4.6 mmol) was added and stirred at room temperature. Iodomethane (7.6 mmol) was added, and the mixture was stirred at room temperature for 3 h. The reaction was monitored and samples were taken to ensure complete reaction. The aqueous phase was extracted twice with water / ethyl acetate (EA), and the organic phases were combined. The organic phase was washed three times with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A9-PM-5-INT01 (0.9 g, 87% yield). 1H NMR (400 MHz, Methanol-d4) δ 8.46 (d, J = 1.9 Hz, 1H), 8.38 (d, J = 5.0 Hz, 1H), 7.41 – 7.28 (m, 1H), 7.26 – 7.16 (m, 1H), 6.87- 6.77 (m, 1H), 6.75 – 6.63 (m, 1H), 4.90 (d, J = 13 Hz, 1H), 4.11 (d, J = 13.0 Hz, 1H), 3.86 – 3.73(m, 1H), 3.71-3.63 (m, 3H), 3.47 (s, 3H), 3.46 – 3.32 (m, 3H), 2.90- 2.74 (m, 2H), 1.88 (d, J = 5.2 Hz, 3H), 1.53 (s, 9H), 1.20 (dd, J = 6.8, 1.9 Hz, 3H), 1.03 (dd, J = 6.8, 2.7 Hz, 3H). MS (ESI) m / z (M+H)+= 677.21.
[0372] Step 5: A9-PM-5-INT01 (0.73 mmol) was dissolved in a 48% aqueous solution of hydrogen bromide, heated to 100°C and refluxed overnight. Sampling and monitoring were performed until the reaction was complete. The aqueous phase was adjusted to alkalinity with sodium carbonate aqueous solution, and extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A9-TM-5 (0.37 g, 90% yield). 1H NMR (400 MHz, Methanol-d4) δ 8.48 (s, 1H), 8.42 (d, J = 5.0 Hz, 1H), 7.24 (d, J = 5.0 Hz, 1H), 7.18 (td, J = 8.4, 6.7 Hz, 1H), 6.62 (d, J = 8.3 Hz, 1H), 6.60 – 6.51 (m, 1H), 4.00 (d, J = 13.3 Hz, 1H), 3.94 (d, J = 3.8 Hz, 1H), 3.52 (s, 4H), 3.50 – 3.38 (m, 3H), 2.91 (t, J = 11.3 Hz, 1H), 2.82 (p, J = 6.8 Hz, 1H), 1.91 (s, 3H), 1.20 (d, J = 6.7 Hz, 3H), 1.05 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 563.40.
[0373] Example 7
[0374] Step 1: A7-1 was dissolved in tetrahydrofuran (100 mL), and N,N-diisopropylethylamine (172.50 mmol) was added. The mixture was cooled to 0°C. Triphosgene (31.63 mmol) was added in portions, and the mixture was brought to room temperature and stirred after the addition was complete. The reaction was monitored by sampling, and the reaction was confirmed to be complete. The reaction was quenched by adding ammonium chloride aqueous solution, and the mixture was stirred and clarified with ethyl acetate. The aqueous phase was extracted twice with EA, and the organic phases were combined, washed with saturated brine, dried, filtered, and concentrated to obtain A7-2-INT01 (11.5 g, 99% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.64 (d, J = 4.9 Hz, 1H), 8.23 (s, 1H), 7.19 (d, J = 4.9 Hz, 1H), 2.52 – 2.38(m, 1H), 1.95 (s, 3H), 1.16 (d, J = 6.7 Hz, 3H), 1.08 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 405.35.
[0375] Step 2: A7-2-INT01 was dispersed in DMF (100 mL), and cesium carbonate (57.50 mmol) was added and stirred at room temperature. Iodomethane (86.25 mmol) was added, and the mixture was stirred at room temperature for 2 h. The reaction was monitored and samples were taken to ensure complete reaction. The aqueous phase was extracted twice with water / ethyl acetate (EA), and the organic phases were combined. The organic phase was washed three times with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain A7-2-INT02 (11 g, 91% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.62 (d, J = 4.9 Hz, 1H), 8.21 (s, 1H), 7.18 (d, J = 4.9 Hz, 1H), 3.71 (s, 3H), 2.46 – 2.52(m, 1H), 1.96 (s, 3H), 1.18 (d, J = 6.7 Hz, 3H), 1.07 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 419.36.
[0376] Step 3: A7-2-INT02 (11.69 mmol), Z3-2-2 compound, dipotassium hydrogen phosphate (51.44 mmol), palladium acetate, and triphenylphosphine, 5% each, were dispersed in 1,4-dioxane (80 mL) and water (40 mL). The mixture was purged with nitrogen three times and heated to 80 °C for 12 hours. After sampling and testing, the reaction was confirmed to be complete. The reaction solution was cooled to room temperature, and water and ethyl acetate (200 mL) were added. The aqueous phase was extracted twice with ethyl acetate, and the combined organic phases were used. The organic phase was washed with sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A7-PM-4-INT05 (5 g, yield 86%). 1H NMR (400 MHz, Chloroform-d) δ 8.54 (d, J = 4.9 Hz, 1H), 8.32 (s, 1H), 8.18 (s, 1H), 7.25 – 7.13 (m, 2H), 6.65 (td, J = 8.4, 1.3 Hz, 2H), 3.74 (s, 3H), 2.50-2.62 (m, 1H), 1.99 (s, 3H), 1.18 (d, J = 6.7 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 495.15.
[0377] Step 4: A7-PM-4-INT05 (4.0 mmol) was dissolved in tetrahydrofuran (15 mL), and an aqueous solution of sodium hydroxide (16 mmol) was added to dissolve it. The mixture was stirred at room temperature for 8 h, and samples were taken for monitoring until the reaction was complete. The reaction was quenched with an aqueous solution of citric acid, and the pH of the aqueous solution was adjusted to a slightly alkaline state. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give A7-PM-4 (1.7 g, 90% yield). MS (ESI) m / z (M+H)+ = 469.14.
[0378] Step 5: A7-PM-4 (3 mmol) was dispersed in DMF (8 mL) solution, N,N-diisopropylethylamine (3 mmol) was added, and Z4-1-2 (3.9 mmol) was added. The mixture was stirred at room temperature for 4 h, and samples were taken for monitoring. The reaction was complete. Water was added, and the aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed three times with water. The organic phase was dried over anhydrous sodium sulfate and concentrated to obtain an oily substance, which was directly added to the next step. (1.7 g, yield 85%). MS (ESI) m / z (M+H)+ = 681.36.
[0379] Step 6: A8-PM-1-4 (2.4 mmol) was weighed and dissolved in THF (20 mL). N,N-diisopropylethylamine (4.2 mmol) and TsCl (3.3 mmol) were added, and the mixture was stirred at room temperature for 3 h. The reaction was monitored by sampling. Once complete, water was added, and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed twice with brine. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain A9-PM-1-2 (1.2 g, 70% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.60 (d, J = 4.9 Hz, 1H), 8.32 (s, 1H), 7.26 – 7.18 (m, 2H), 6.73 – 6.61 (m, 2H), 5.00 (d, J = 13.4 Hz, 1H), 4.37 – 4.20 (m, 1H), 3.58 – 3.46 (m, 4H), 3.42-3.30 (m, 2H), 3.28-3.15 (m, 1H), 2.99-2.87 (m, 1H), 2.83 – 2.70 (m, 1H), 1.92 (s, 3H), 1.55 (s, 9H), 1.23 (d, J = 6.7 Hz, 3H), 1.10 (d, J = 6.7 Hz, 3H). MS (ESI) m / z (M+H)+= 663.40.
[0380] Example 8
[0381] Step 1: Under nitrogen protection, LiHMDS (bis-(trimethylsilyl)amine lithium) (4.0 eq) was added to a reaction flask and cooled to -10°C. Al-1 (1.0 eq) and 2-isopropyl-4-methylpyridin-3-amine S4 (1.1 eq) were dissolved in anhydrous tetrahydrofuran, and the tetrahydrofuran solution of Al-1 and S4 was added dropwise to the LiHMDS reactor while maintaining the temperature at -5°C to 0°C. The reaction was maintained at -5°C to 0°C for 4 hours. Sampling was performed to monitor the reaction, which was confirmed to be complete. The reaction was quenched with water, the solvent was evaporated, and water and methyl tributyl ether were added. The pH was adjusted to approximately 6 with concentrated hydrochloric acid, resulting in solid precipitation. Stirring continued for another half hour. The solid was filtered, washed successively with methyl tributyl ether and water, and dried to obtain E3-1 (27.0 g, 90% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.91(s, 1H), 8.34 (d, J= 4.8 Hz, IH), 8.27 (s, 1H), 7.18 (d, J= 4.8 Hz, 1H), 3.17-3.07(m, 1H), 2.13 (s, 3H), 1.12 (s, 3H), 1.11 (s, 3H). MS (ESI) m / z (M+H)+= 340.50.
[0382] Step 2: E4-1 (23.62 mmol) was dissolved in CHCl3 (40 mL), and E3-1 (11.81 mmol) was added to the solution. The reaction was carried out overnight at room temperature until the starting material was completely converted. The solvent was removed by concentration under reduced pressure, and the semi-solid was purified by column chromatography. The semi-solid was purified by slurrying with petroleum ether and methyl tributyl ether, filtered, washed, and dried to obtain E5-1 (3.85 g, yield 75%). 1H NMR (400 MHz, Chloroform-d) δ 8.40 (d, J = 4.9 Hz, 1H), 8.00 (d, J = 2.4 Hz, 2H), 7.03 (d, J = 5.0 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 3.48 – 3.05 (m, 1H), 2.17 (s, 3H), 1.40 (t, J = 7.2 Hz, 3H), 1.21 (d, J = 6.8 Hz, 6H).
[0383] Step 3: E5-1 (23.0 mmol) was dissolved in THF (100 mL), and then NaOH (45.9 mmol) was added. The mixture was stirred at room temperature for 5 hours until the starting material was completely converted. The solution was adjusted to neutral with acetic acid, and then extracted with ethyl acetate and water to separate the layers. The organic layers were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain A5-1 (9.0 g, 98% yield).
[0384] Example 9 Compound A7-1 (0.022 mol, 1.0 eq) was dissolved in 20 mL of DMF, and compound Z4-1-1 (0.022 mol, 1.0 eq) was added. The reaction was carried out overnight at 32 °C. The conversion of the starting material was confirmed by LC-MS. The mixture was extracted with 400 mL of ethyl acetate and 200 mL of water to separate the layers. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and column chromatography was performed to obtain compound A8-1-1 (0.021 mol) in 95% yield.
[0385] Example 10 Compound A7-1 (0.022 mol, 1.0 eq) was dissolved in 20 mL of DMF, and compound Z4-1-1 (0.022 mol, 1.0 eq) was added. Sodium bicarbonate (0.011 mol, 0.5 eq) was added, and the reaction was carried out overnight at 32 °C. The conversion of the starting material was confirmed by LC-MS. The mixture was extracted with 400 mL of ethyl acetate and 200 mL of water to separate the layers. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and column chromatography was performed to obtain compound A8-1-1 (0.021 mol) in 95% yield.
[0386] The exemplary embodiments of the present invention have been described above. It should be understood that the scope of protection of this application is not limited to the exemplary embodiments described above. Any modifications, equivalent substitutions, improvements, etc., made by those skilled in the art within the spirit and principles of the present invention should be included within the scope of protection of this application.
Claims
1. A method for preparing a compound of formula A2 or its optical isomer, comprising the following steps: contacting a compound of formula A1 and a compound of formula Z1 to prepare a compound of formula A2; wherein, R1 and R2 are independently selected from -H, -F, -Cl, -Br or -I; R3 is selected from -F, -Cl, -Br or -I; R4 is selected from ethyl, n-propyl, isopropyl, n-butyl, secondary butyl, isobutyl or tertiary butyl.
2. A method for preparing the compound of formula A2 or its optical isomer as described in claim 1, wherein, The preparation of compound A2 includes the following steps: reacting compound A1 with a acetylation reagent to prepare a acetylated compound; or reacting compound A1 with an azide reagent to prepare an acetylated azide intermediate; and reacting the acetylated compound or the acetylated azide intermediate with compound Z1 to form an acetazole ring, thereby preparing compound A2.
3. A compound of formula A2 or its optical isomer: wherein, The definitions of R1 to R4 are as described in request item 1.
4. The compound of formula A2 as claimed in claim 3, or an optical isomer thereof, wherein the compound of formula A2 is , , , , , , or.
5. A method for preparing a compound of formula A3 or its optical isomer, comprising the following steps: hydrolyzing a compound of formula A2 to prepare a compound of formula A3; wherein, The definitions of R1 to R4 are as described in request item 1.
6. A method for preparing a compound of formula A4 or its optical isomer, comprising the following steps: hydrolyzing a compound of formula A2 to prepare a compound of formula A3; and subjecting the compound of formula A3 and a compound of formula Z2 to an amination reaction to prepare a compound of formula A4; wherein, R1 to R4 are defined as described in claim 1; R5 and R6 are each independently selected from -H, -F, -Cl, C1-6 alkyl or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy are optionally substituted by 1, 2 or 3 Ra; R7 is independently selected each time it appears from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy are optionally substituted by 1, 2 or 3 Ra; Ra is independently selected each time it appears from -H, -F, -Cl, -Br, -I, -OH, -NH2, -CH3, -CF3, -C2H5, -CN, -SF5, -CHO, -COOH or -C(=O)NH2; m is selected from 0, 1 or 2.
7. A method for preparing the compound of formula A4 or its optical isomer as described in claim 6, wherein, The preparation of compound A4 includes the following steps: reacting compound A3 with a acetylation reagent to prepare a acetylated compound; and reacting the acetylated compound with compound Z2 to prepare compound A4.
8. A compound of formula A4 or an optical isomer thereof: wherein, The definitions of R1~R3 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6.
9. The compound of formula A4 as claimed in claim 8, or an optical isomer thereof, wherein the compound of formula A4 is , , , , , , or.
10. A method for preparing a compound of formula E5 or an optical isomer thereof, comprising the following steps: subjecting a compound of formula E3 to a compound of formula E4 via an addition cyclization reaction to prepare a compound of formula E5; wherein, R1~R2 are defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R4a is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, secondary butyl, isobutyl or tertiary butyl.
11. A compound of formula E5 or an optical isomer thereof: wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definition of R4a is as described in Request 10.
12. The E5 compound or an optical isomer thereof as claimed in claim 11, wherein the E5 compound is, , or .
13. A method for preparing a compound of formula AA5 or its optical isomer, comprising the following steps: subjecting a compound of formula A4 to a nucleophilic substitution reaction to prepare a compound of formula AA5; or, contacting a compound of formula E5 with a base to undergo an amino-ester exchange reaction to prepare a compound of formula AA5; wherein, The definitions of R1~R3 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definition of R4a is as described in Request 10.
14. A compound of formula A5 or an optical isomer thereof: wherein, R1~R2 are defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R13 is selected from H or methyl.
15. The compound of formula A5 as claimed in claim 14 or an optical isomer thereof, wherein the compound of formula A5 is , , , , , , or.
16. The compound of formula A5 as claimed in claim 14, or an optical isomer thereof, wherein, When R13 is methyl, the compound of formula A5 is prepared by: hydrolyzing and ring-opening the compound of formula AA5 to prepare the compound of formula A7'; and reacting the compound of formula A7' with substance P to form a ring to prepare the compound of formula A5; wherein the substance P is selected from acetyl chloride, acetic anhydride or trimethyl orthoacetate.
17. A method for preparing a compound of formula A5-P or its optical isomer, comprising the following steps: coupling a compound of formula A5 with a compound of formula Z3 to prepare a compound of formula A5-P; wherein, The Z3 compound is a compound of formula Z3-1 or Z3-2; ; R1~R2 are defined as described in claim 1; R5~R7 and m are defined as described in claim 6; R13 is defined as described in claim 14; RZ, each time it appears, is independently selected from H or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted by 1, 2 or 3 Rb; R10 and R11 are each independently selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy are optionally substituted by 1, 2 or 3 Rb; R12, each time it appears, is independently selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy are optionally substituted by 1, 2 or 3 Rb; Each occurrence of Rb is independently selected from -H, -F, -Cl, -Br, -I, -OH, -NH2, -CH3, -CF3, -C2H5, -CN, -SF5, -CHO, -COOH, or -C(=O)NH2; n is selected from 0, 1, 2, or 3.
18. A compound of formula A5-P or its optical isomer: wherein, R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R13 is defined as described in Request 14; R10~R12 and n are defined as described in Request 17.
19. The compound of formula A5-P as claimed in claim 18 or an optical isomer thereof, wherein the compound of formula A5-P is, , or .
20. A method for preparing a compound of formula A6, a compound of formula D6, or an optical isomer thereof, comprising the following steps: contacting a compound of formula A5 with a substance L, and performing chiral resolution to prepare a compound of formula A6 or a compound of formula D6; wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definition of R13 is as described in Request 14; the substance L is one or more of S-binaphthol phosphate, D-3-bromocamphor-10-sulfonic acid, D-(+)-camphor sulfonic acid, S-3,3'-bis(triphenylsilyl)binaphthol phosphonate, S-3,3'-bis(3,5-bistrifluoromethoxyphenyl)-1,1'-bi-(2-naphthol) phosphate and S-3,3'-bis(2,4,6-triisopropylphenyl)-1,1'-binaphthol-2,2'-bisphosphonate, or R-binaphthol phosphate, L-3-bromocamphor-10-sulfonic acid, L-(+)-camphor sulfonic acid, R-3,3'-bis(triphenylsilyl)binaphthol phosphonate, R One or more of R-3,3'-bis(3,5-bistrifluoromethoxyphenyl)-1,1'-bi-(2-naphthol) phosphate and R-3,3'-bis(2,4,6-triisopropylphenyl)-1,1'-binaphthyl-2,2'-bisphosphate.
21. A method for preparing the compound of formula A6, the compound of formula D6, or an optical isomer thereof as described in claim 20, wherein, The chiral resolution includes the following steps: reacting compound A5 and substance L with a salt to prepare a salt-type intermediate compound; reacting the salt-type intermediate compound with a free reagent to prepare compound A6 or compound D6.
22. A compound of formula A6, a compound of formula D6, substance N, or an optical isomer thereof, wherein substance N comprises the compound of formula A6 and the compound of formula D6: wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definition of R13 is as described in Request 14.
23. The compound of formula A6, the compound of formula D6, substance N or an optical isomer thereof as claimed in claim 22, wherein the compound of formula A6 is , , , , , , or; or, the compound of formula D6 is , , , , , , or.
24. The compound of formula A6, the compound of formula D6, substance N or an optical isomer thereof as claimed in claim 22, wherein the substance N is a mixture of any of the following groups: mixtures of and, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of, mixtures of.
25. A method for preparing a compound of formula A6-P, a compound of formula D6-P, or an optical isomer thereof, comprising the following steps: contacting a compound of formula A5-P with a substance L and performing chiral resolution to prepare a compound of formula A6-P or a compound of formula D6-P; or coupling a compound of formula A6 or a compound of formula D6 with a compound of formula Z3 to prepare a compound of formula A6-P or a compound of formula D6-P; wherein, The Z3 compound is a compound of formula Z3-1 or Z3-2; The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of RZ, R10~R12 and n are as described in Request 17; the definition of R13 is as described in Request 14; the definition of the substance L is as described in Request 20; the steps and conditions for the chiral separation are as described in Request 20 or 21.
26. A compound of formula A6-P, a compound of formula D6-P, a substance M, or an optical isomer thereof, wherein the substance M comprises the compound of formula A6-P and the compound of formula D6-P: wherein, R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R10~R12 and n are defined as described in Request 17; R13 is defined as described in Request 14.
27. The compound of formula A6-P, the compound of formula D6-P, substance M or an optical isomer thereof as claimed in claim 26, wherein the compound of formula A6-P is, or; or, the compound of formula D6-P is, or.
28. The compound of formula A6-P, the compound of formula D6-P, substance M or an optical isomer thereof as claimed in claim 26, wherein the substance M is a mixture of any of the following groups: a mixture of and, a mixture of, a mixture of, and, a mixture of.
29. A method for preparing a compound of formula A7, a compound of formula A7', its optical isomer, or a pharmaceutically acceptable salt thereof, comprising the following steps: subjecting a compound of formula A5 to a hydrolytic ring-opening reaction to prepare a compound of formula A7' or a pharmaceutically acceptable salt thereof; or subjecting a compound of formula A6 to a hydrolytic ring-opening reaction to prepare a compound of formula A7 or a pharmaceutically acceptable salt thereof; or contacting a compound of formula A7' or a pharmaceutically acceptable salt thereof with a chiral acid to perform chiral resolution to prepare a compound of formula A7 or a pharmaceutically acceptable salt thereof; wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definition of R13 is as described in Request 14.
30. A method for preparing the A7 compound, the A7' compound, its optical isomer, or a pharmaceutically acceptable salt thereof as described in claim 29, wherein, The compound of formula A7 is prepared by neutralization reaction of a pharmaceutically acceptable salt of the compound of formula A7. And / or the compound of formula A7' is prepared by neutralization reaction with a pharmaceutically acceptable salt of the compound of formula A7'.
31. A method for preparing a compound of formula A7-P, its optical isomer, or a pharmaceutically acceptable salt thereof, comprising the following steps: subjecting a compound of formula A6-P to a hydrolytic ring-opening reaction to prepare a compound of formula A7-P or a pharmaceutically acceptable salt thereof; or subjecting a compound of formula A7 or a pharmaceutically acceptable salt thereof to a coupling reaction with a compound of formula Z3 to prepare a compound of formula A7-P or a pharmaceutically acceptable salt thereof; wherein, The Z3 compound is a compound of formula Z3-1 or Z3-2; R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; RZ, R10~R12 and n are defined as described in Request 17; R13 is defined as described in Request 14.
32. A method for preparing a compound of formula A7'-P, its optical isomer, or a pharmaceutically acceptable salt thereof, comprising the following steps: subjecting a compound of formula A5-P to a hydrolytic ring-opening reaction to prepare a compound of formula A7'-P or a pharmaceutically acceptable salt thereof; or subjecting a compound of formula A7' or a pharmaceutically acceptable salt thereof to a coupling reaction with a compound of formula Z3 to prepare a compound of formula A7'-P or a pharmaceutically acceptable salt thereof; wherein, The Z3 compound is a compound of formula Z3-1 or Z3-2; R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; RZ, R10~R12 and n are defined as described in Request 17; R13 is defined as described in Request 14.
33. A compound of formula A7, a compound of formula A7', a compound of formula A7-P, a compound of formula A7'-P, an optical isomer thereof, or a pharmaceutically acceptable salt thereof: wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of R10~R12 and n are as described in Request 17.
34. The A7 compound, A7' compound, A7-P compound, A7'-P compound, optical isomer thereof or pharmaceutically acceptable salt thereof as claimed in claim 33, wherein the A7 compound is, or; or, the A7' compound is, or; or, the A7-P compound is or; or, the A7'-P compound is or.
35. A method for preparing a compound of formula A7-M, a compound of formula A7'-M, its optical isomer, or a pharmaceutically acceptable salt thereof, comprising the following steps: contacting the compound of formula A7 or a pharmaceutically acceptable salt thereof with a carbonyl-containing compound to perform a ring-closure reaction, to prepare a compound of formula A7-intermediate 1 or a pharmaceutically acceptable salt thereof; contacting the compound of formula A7-intermediate 1 or a pharmaceutically acceptable salt thereof with a methylating agent to perform a methylation reaction, to prepare a compound of formula A7-intermediate 2 or a pharmaceutically acceptable salt thereof; hydrolyzing the compound of formula A7-intermediate 2 or a pharmaceutically acceptable salt thereof to prepare a compound of formula A7-M or a pharmaceutically acceptable salt thereof; or contacting the compound of formula A7' or a pharmaceutically acceptable salt thereof with a carbonyl-containing compound to perform a ring-closure reaction, to prepare a compound of formula A7'-intermediate 1 or a pharmaceutically acceptable salt thereof; contacting the compound of formula A7'-intermediate 1 or a pharmaceutically acceptable salt thereof with a methylating agent to perform a methylation reaction, to prepare a compound of formula A7'-intermediate 2 or a pharmaceutically acceptable salt thereof; The compound of formula A7'-intermediate 2 or a pharmaceutically acceptable salt thereof is hydrolyzed to prepare a compound of formula A7'-M or a pharmaceutically acceptable salt thereof; wherein... The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6.
36. A method for preparing a compound of formula A7-PM, a compound of formula A7'-PM, its optical isomer, or a pharmaceutically acceptable salt thereof, comprising the following steps: contacting a compound of formula A7-P or a pharmaceutically acceptable salt thereof with a carbonyl-containing compound to perform a ring-closure reaction, thereby preparing a compound of formula A7-P-intermediate 1 or a pharmaceutically acceptable salt thereof; contacting a compound of formula A7-P-intermediate 1 or a pharmaceutically acceptable salt thereof with a methylating agent to perform a methylation reaction, thereby preparing a compound of formula A7-P-intermediate 2 or a pharmaceutically acceptable salt thereof; hydrolyzing a compound of formula A7-P-intermediate 2 or a pharmaceutically acceptable salt thereof to prepare a compound of formula A7-PM or a pharmaceutically acceptable salt thereof; or contacting a compound of formula A7 or a pharmaceutically acceptable salt thereof with a carbonyl-containing compound to perform a ring-closure reaction, thereby preparing a compound of formula A7-PM-intermediate 1 or a pharmaceutically acceptable salt thereof; To prepare compound A7-PM-intermediate 1 or its pharmaceutically acceptable salt by contacting a methylating agent and carrying out a methylation reaction, compound A7-PM-intermediate 2 or its pharmaceutically acceptable salt is prepared; to prepare compound A7-PM-intermediate 3 by coupling compound A7-PM-intermediate 2 or its pharmaceutically acceptable salt with compound Z3; to prepare compound A7-PM-intermediate 3 by hydrolysis of compound A7-PM-intermediate 3 or its pharmaceutically acceptable salt; or to prepare compound A7'-P-intermediate 1 or its pharmaceutically acceptable salt by contacting a carbonyl-containing compound and carrying out a ring-closing reaction, compound A7'-P-intermediate 1 or its pharmaceutically acceptable salt is prepared; to prepare compound A7'-P-intermediate 2 or its pharmaceutically acceptable salt by contacting a methylating agent and carrying out a methylation reaction. The compound of formula A7'-P-intermediate 2 or its pharmaceutically acceptable salt is prepared by hydrolysis; wherein... The Z3 compound is a compound of formula Z3-1 or Z3-2; R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; RZ, R10~R12 and n are defined as described in Request 17.
37. A compound of formula A7-M, a compound of formula A7'-M, a compound of formula A7-PM, a compound of formula A7'-PM, an optical isomer thereof, or a pharmaceutically acceptable salt thereof: wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of R10~R12 and n are as described in Request 17.
38. The A7-M compound, A7'-M compound, A7-PM compound, A7'-PM compound, optical isomer thereof or pharmaceutically acceptable salt thereof as claimed in claim 37, wherein the A7-M compound is, or; or, the A7'-M compound is, or; or, the A7-PM compound is or; or, the A7'-PM compound is or.
39. A method for preparing a compound of formula AA7, a compound of formula AA7', a compound of formula AA7-P, a compound of formula AA7'-P, a compound of formula AA7-M, a compound of formula AA7'-M, a compound of formula AA7-PM, a compound of formula AA7'-PM, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, comprising the following steps: subjecting a compound of formula A7, a compound of formula A7', a compound of formula A7-P, a compound of formula A7'-P, a compound of formula A7-M, a compound of formula A7'-M, a compound of formula A7-PM, or a compound of formula A7'-PM to a hydroxyl protection reaction to prepare the compound of formula AA7, a compound of formula AA7', a compound of formula AA7-P, a compound of formula AA7'-P, a compound of formula AA7-M, a compound of formula AA7'-M, a compound of formula AA7-PM, or a compound of formula AA7'-PM; wherein, R1~R2 are defined as described in claim 1; R5~R7 and m are defined as described in claim 6; R10~R12 and n are defined as described in claim 17; R14 is -O-(S=O)2-R15, -OC(=O)R16, or -O-R17; R15 is selected from methyl or phenyl, wherein the methyl or phenyl group is optionally substituted by 1, 2, or 3 Rd groups; R16 is selected from methyl or phenyl, wherein the methyl or phenyl group is optionally substituted by 1, 2, or 3 Rd groups; R17 is selected from hydroxyl protecting groups; each time Rd appears, it is independently selected from H, F, methyl, or nitro groups.
40. A compound of formula AA7, a compound of formula AA7', a compound of formula AA7-P, a compound of formula AA7'-P, a compound of formula AA7-M, a compound of formula AA7'-M, a compound of formula AA7-PM, a compound of formula AA7'-PM, an optical isomer thereof, or a pharmaceutically acceptable salt thereof: wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of R10~R12 and n are as described in Request 17; and the definition of R14 is as described in Request 39.
41. The compound of formula AA7, formula AA7', formula AA7-P, formula AA7'-P, formula AA7-M, formula AA7'-M, formula AA7-PM, formula AA7'-PM, optical isomers thereof or pharmaceutically acceptable salts thereof as claimed in claim 40, wherein R14 is -O-TBS, -O-MOM, -OTs, -Oms, -OAc or -OBz.
42. The use of a compound of formula Z4 in the preparation of compounds of formula A8, A8', A8-P, A8'-P, A8-M, A8'-M, A8-PM, A8'-PM, A9, A9', A9-P, A9'-P, A9-M, A9'-M, A9-PM, A9'-PM, their optical isomers, or pharmaceutically acceptable salts thereof, wherein, The definitions of R1~R2 are as described in claim 1; the definitions of R5~R7 and m are as described in claim 6; the definitions of R10~R12 and n are as described in claim 17; when the dashed line is a single bond, Y is CH(R9), Z is CH2, and W is selected from N(R8); when the dashed line is absent, Y is H, R8, or a hydroxyl protecting group, Z is H, and W is selected from NH or O; R8 is selected from an amino protecting group, Ns, acrylonitrile, or 3-chloropropylated; R9 is selected from -H, -F, -Cl, -Br, -I, hydroxyl, amino, nitro, cyano, C1-6 alkyl, or C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy are optionally substituted by 1, 2, or 3 Rc; Each occurrence of Rc is independently selected from -H, -F, -Cl, -Br, -I, -OH, -NH2, -CH3, -CF3, -C2H5, -CN, -SF5, -CHO, -COOH, or -C(=O)NH2.
43. The application as described in claim 42, wherein, The compound of formula Z4 is selected from or; when R9 is not -H, the compound of formula Z4-1 is.
44. The application as described in claim 43, wherein the compound of formula Z4-1 is , , , , , , or; or, wherein the compound of formula Z4-2 is , , , , or.
45. The application as described in claim 43, wherein, The preparation of compound Z4-1 includes the following steps: reacting compound Z4a with dibutyl dicarbonate via an amino protection reaction to prepare compound Z4b; and reacting compound Z4b with sulfonium dichloroethylene via a cyclization reaction to prepare compound Z4-1.
46. A method for preparing a compound of formula A8, a compound of formula A8', an optical isomer thereof, or a pharmaceutically acceptable salt thereof, comprising the following steps: reacting a compound of formula A7 or a pharmaceutically acceptable salt thereof with a compound of formula Z4 via a acetylation reaction to prepare a compound of formula A8 or a pharmaceutically acceptable salt thereof; or reacting a compound of formula A6 via a hydrolysis ring-opening reaction, and after the hydrolysis ring-opening reaction is completed, adding a compound of formula Z4 and reacting via a acetylation reaction to prepare a compound of formula A8 or a pharmaceutically acceptable salt thereof; or reacting a compound of formula A7' or a pharmaceutically acceptable salt thereof with a compound of formula Z4 via a acetylation reaction to prepare a compound of formula A8' or a pharmaceutically acceptable salt thereof; or reacting a compound of formula A5 via a hydrolysis ring-opening reaction, and after the hydrolysis ring-opening reaction is completed, adding a compound of formula Z4 and reacting via a acetylation reaction to prepare a compound of formula A8' or a pharmaceutically acceptable salt thereof; wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definition of R13 is as described in Request 14; and the definitions of W, Y and Z are as described in Request 42.
47. A method for preparing a compound of formula A8-P, a compound of formula A8'-P, its optical isomer, or a pharmaceutically acceptable salt thereof, comprising the following steps: reacting a compound of formula A7-P or a pharmaceutically acceptable salt thereof with a compound of formula Z4 via a acetylation reaction to prepare a compound of formula A8-P or a pharmaceutically acceptable salt thereof; or reacting a compound of formula A6-P via a hydrolysis ring-opening reaction, and after the hydrolysis ring-opening reaction is completed, adding a compound of formula Z4 and reacting via a acetylation reaction to prepare a compound of formula A8-P or a pharmaceutically acceptable salt thereof; or reacting a compound of formula A7'-P or a pharmaceutically acceptable salt thereof with a compound of formula Z4 via a acetylation reaction to prepare a compound of formula A8'-P or a pharmaceutically acceptable salt thereof; or reacting a compound of formula A5-P via a hydrolysis ring-opening reaction, and after the hydrolysis ring-opening reaction is completed, adding a compound of formula Z4 and reacting via a acetylation reaction to prepare a compound of formula A8'-P or a pharmaceutically acceptable salt thereof; wherein, R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R10~R12 and n are defined as described in Request 17; R13 is defined as described in Request 14; W, Y and Z are defined as described in Request 42.
48. A method for preparing a compound of formula A8-M, a compound of formula A8'-M, its optical isomer, or a pharmaceutically acceptable salt thereof, comprising the following steps: reacting a compound of formula A7-M or a pharmaceutically acceptable salt thereof with a compound of formula Z4 via a acetylation reaction to prepare a compound of formula A8-M or a pharmaceutically acceptable salt thereof; or reacting a compound of formula A7'-M or a pharmaceutically acceptable salt thereof with a compound of formula Z4 via a acetylation reaction to prepare a compound of formula A8'-M or a pharmaceutically acceptable salt thereof; wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of W, Y and Z are as described in Request 42.
49. A method for preparing a compound of formula A8-PM, a compound of formula A8'-PM, its optical isomer, or a pharmaceutically acceptable salt thereof, comprising the following steps: reacting a compound of formula A7-PM or a pharmaceutically acceptable salt thereof with a compound of formula Z4 via a ring-opening reaction to prepare a compound of formula A8-PM or a pharmaceutically acceptable salt thereof; or reacting a compound of formula A7'-PM or a pharmaceutically acceptable salt thereof with a compound of formula Z4 via a amide reaction to prepare a compound of formula A8'-PM or a pharmaceutically acceptable salt thereof; wherein, R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R10~R12 and n are defined as described in Request 17; W, Y and Z are defined as described in Request 42.
50. A compound of formula A8, a compound of formula A8', a compound of formula A8-P, a compound of formula A8'-P, a compound of formula A8-M, a compound of formula A8'-M, a compound of formula A8-PM, a compound of formula A8'-PM, an optical isomer thereof, or a pharmaceutically acceptable salt thereof: wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of R10~R12 and n are as described in Request 17; and the definitions of W, Y and Z are as described in Request 42.
51. The compound of formula A8, formula A8', formula A8-P, formula A8'-P, formula A8-M, formula A8'-M, formula A8-PM, formula A8'-PM, optical isomers thereof, or pharmaceutically acceptable salts thereof, as described in claim 50, wherein, The compound of formula A8 is selected from or; the compound of formula A8' is selected from or; the compound of formula A8-M is selected from or; the compound of formula A8'-M is selected from or; the compound of formula A8-P is selected from or; the compound of formula A8'-P is selected from or; the compound of formula A8-PM is selected from or; the compound of formula A8'-PM is selected from or.
52. The compound of formula A8, formula A8', formula A8-P, formula A8'-P, formula A8-M, formula A8'-M, formula A8-PM, formula A8'-PM, optical isomers thereof, or pharmaceutically acceptable salts thereof, as described in claim 50, wherein, The compound of formula A8-1 is , , , , , , , , , , or; or, the compound of formula A8-2 is , , , or; or, the compound of formula A8'-1 is , , , , , , , , , , or; or, the compound of formula A8'-2 is , , , or; or, the compound of A8-M-1 is , , , , , , , , , , or; or, the compound of A8-M-2 is , , , or; or, the compound of formula A8'-M-1 is , , , , , , , , , , , or; or, the compound of formula A8'-M-2 is , , , or ; or, the A8-P-1 compound is, , , , , , or; or, the A8-P-2 compound is, , , or; or, the A8'-P-1 compound is, , , , , or; or, the A8'-P-2 compound is, , , or; or, the A8-PM-1 compound is, , , , , or; or, the A8-PM-2 compound is, , , or; or, the A8'-PM-1 compound is, , , , , or; or, the A8'-PM-2 compound is, , , or; or, the A8'-PM-1 compound is, , , , , or; or, the A8'-PM-2 compound is, , , or.
53. A method for preparing a compound of formula AA8, a compound of formula AA8', a compound of formula AA8-P, a compound of formula AA8'-P, a compound of formula AA8-M, a compound of formula AA8'-M, a compound of formula AA8-PM, a compound of formula AA8'-PM, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, comprising the following steps: subjecting a compound of formula AA7, a compound of formula AA7', a compound of formula AA7-P, a compound of formula AA7'-P, a compound of formula AA7-M, a compound of formula AA7'-M, a compound of formula AA7-PM, a compound of formula AA7'-PM, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, to a amide reaction with a compound of formula Z4 to prepare a compound of formula AA8, a compound of formula AA8', a compound of formula AA8-P, a compound of formula AA8'-P, a compound of formula AA8-M, a compound of formula AA8'-M, a compound of formula AA8-PM, a compound of formula AA8'-PM, an optical isomer thereof, or a pharmaceutically acceptable salt thereof; wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of R10~R12 and n are as described in Request 17; the definition of R14 is as described in Request 39; The definitions of W, Y, and Z are as described in claim 42; the conditions for the amide reaction are as described in any one of claims 46 to 49.
54. A compound of formula AA8, a compound of formula AA8', a compound of formula AA8-P, a compound of formula AA8'-P, a compound of formula AA8-M, a compound of formula AA8'-M, a compound of formula AA8-PM, a compound of formula AA8'-PM, an optical isomer thereof, or a pharmaceutically acceptable salt thereof: wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of R10~R12 and n are as described in Request 17; the definition of R14 is as described in Request 39; The definitions of W, Y, and Z are as described in request item 42.
55. A method for preparing a compound of formula A9, a compound of formula A9', or an optical isomer thereof, comprising the following steps: reacting a compound of formula A8 or a pharmaceutically acceptable salt thereof with a cyclization reaction to prepare a compound of formula A9; or reacting a compound of formula A6 with a hydrolysis ring-opening reaction, adding a compound of formula Z4 after the hydrolysis ring-opening reaction, performing a acetylation reaction, and then performing a cyclization reaction after the acetylation reaction to prepare a compound of formula A9; or reacting a compound of formula A8' or a pharmaceutically acceptable salt thereof with a cyclization reaction to prepare a compound of formula A9'; or reacting a compound of formula A5 with a hydrolysis ring-opening reaction, adding a compound of formula Z4 after the hydrolysis ring-opening reaction, performing a acetylation reaction, and then performing a cyclization reaction after the acetylation reaction to prepare a compound of formula A9'; wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definition of R13 is as described in Request 14; and the definitions of W, Y and Z are as described in Request 42.
56. A method for preparing a compound of formula A9, a compound of formula A9', or an optical isomer thereof as described in claim 55, wherein, The compound of formula A8 is a compound of formula A8-1, and the compound of formula A9-1 is prepared; Alternatively, the compound of formula A8 may be a compound of formula A8-2, and a compound of formula A9-2 may be prepared; or the compound of formula A9-2 may be contacted with an ethyl derivative, and the compound of formula A9-1 may be prepared by nucleophilic substitution and reductive amination reaction to achieve cyclization; or the compound of formula A8' may be a compound of formula A8'-1, and a compound of formula A9'-1 may be prepared. Alternatively, the compound of formula A8' may be an A8'-2 compound, and a compound of formula A9'-2 may be prepared; or the compound of formula A9'-2 may be contacted with an ethyl derivative, and cyclized through nucleophilic substitution and reductive amination reactions to prepare the compound of formula A9'-1; wherein, R1~R2 are defined as described in claim 1; R5~R7 and m are defined as described in claim 6; W, Y, R8 and R9 are defined as described in claim 42.
57. A method for preparing a compound of formula A9-P, a compound of formula A9'-P, or an optical isomer thereof, comprising the following steps: performing a cyclization reaction on a compound of formula A8-P or a pharmaceutically acceptable salt thereof to prepare a compound of formula A9-P; or performing a hydrolysis ring-opening reaction on a compound of formula A6-P, adding a compound of formula Z4 after the hydrolysis ring-opening reaction, performing a acetylation reaction, and performing a cyclization reaction after the acetylation reaction to prepare a compound of formula A9-P; or performing a cyclization reaction on a compound of formula A8'-P or a pharmaceutically acceptable salt thereof to prepare a compound of formula A9'-P; or performing a hydrolysis ring-opening reaction on a compound of formula A5-P, adding a compound of formula Z4 after the hydrolysis ring-opening reaction, performing an acetylation cyclization reaction, and performing a cyclization reaction after the acetylation reaction to prepare a compound of formula A9'-P; wherein, R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R10~R12 and n are defined as described in Request 17; W, Y and Z are defined as described in Request 42; R13 is defined as described in Request 14.
58. A method for preparing a compound of formula A9-P, a compound of formula A9'-P, or an optical isomer thereof as described in claim 57, wherein, The compound of formula A8-P is a compound of formula A8-P-1, and the compound of formula A9-P-1 is prepared. Alternatively, the compound of formula A8-P may be an A8-P-2 compound, and a compound of formula A9-P-2 may be prepared. Alternatively, the compound of formula A9-P-2 can be contacted with an ethyl derivative and cyclized through nucleophilic substitution and reductive amination to prepare the compound of formula A9-P-1. Alternatively, the compound of formula A8'-P may be a compound of formula A8'-P-1, and a compound of formula A9'-P-1 may be prepared. Alternatively, the compound of formula A8'-P may be an A8'-P-2 compound, and a compound of formula A9'-P-2 may be prepared. Alternatively, the compound of formula A9'-P-2 may be contacted with an ethyl derivative and cyclized via nucleophilic substitution and reductive amination to prepare the compound of formula A9'-P-1; wherein, R2 is defined as described in claim 1; R5~R7 and m are defined as described in claim 6; R10~R12 and n are defined as described in claim 17; and W, Y, R8 and R9 are defined as described in claim 39.
59. A method for preparing a compound of formula A9-M, a compound of formula A9'-M, or an optical isomer thereof, comprising the following steps: reacting a compound of formula A8-M or a pharmaceutically acceptable salt thereof with a cyclization reaction to prepare a compound of formula A9-M; or reacting a compound of formula A8'-M or a pharmaceutically acceptable salt thereof with a cyclization reaction to prepare a compound of formula A9'-M; wherein, The definitions of R1~R2 are as described in Request 1; the definitions of R5~R7 and m are as described in Request 6; the definitions of W, Y and Z are as described in Request 42.
60. A method for preparing a compound of formula A9-M, a compound of formula A9'-M, or an optical isomer thereof as described in claim 59, wherein, The compound of formula A8-M is a compound of formula A8-M-1, and the compound of formula A9-M-1 is prepared; or the compound of formula A8-M is a compound of formula A8-M-2, and the compound of formula A9-M-2 is prepared; or the compound of formula A9-M-2 is contacted with an ethyl derivative, and the compound of formula A9-M-1 is prepared by nucleophilic substitution and reductive amination reaction; or the compound of formula A8'-M is a compound of formula A8'-M-1, and the compound of formula A9'-M-1 is prepared. Alternatively, the compound of formula A8'-M may be an A8'-M-2 compound, and a compound of formula A9'-M-2 may be prepared; or the compound of formula A9'-M-2 may be contacted with an ethyl derivative, and cyclized through nucleophilic substitution and reductive amination reactions to prepare the compound of formula A9'-M-1; wherein, R1~R2 are defined as described in claim 1; R5~R7 and m are defined as described in claim 6; and W, Y, R8 and R9 are defined as described in claim 42.
61. A method for preparing a compound of formula A9-PM, a compound of formula A9'-PM, or an optical isomer thereof, comprising the following steps: reacting a compound of formula A8-PM or a pharmaceutically acceptable salt thereof with a cyclization reaction to prepare a compound of formula A9-PM; or reacting a compound of formula A8'-PM or a pharmaceutically acceptable salt thereof with a cyclization reaction to prepare a compound of formula A9'-PM; wherein, R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R10~R12 and n are defined as described in Request 17; W, Y and Z are defined as described in Request 42.
62. A method for preparing a compound of formula A9-PM, a compound of formula A9'-PM, or an optical isomer thereof as described in claim 61, wherein, The compound of formula A8-PM is a compound of formula A8-PM-1, and the compound of formula A9-PM-1 is prepared; or the compound of formula A8-PM is a compound of formula A8-PM-2, and the compound of formula A9-PM-2 is prepared; or the compound of formula A9-PM-2 is contacted with an ethyl derivative, and the compound of formula A9-PM-1 is prepared by nucleophilic substitution and reductive amination; or the compound of formula A8'-PM is a compound of formula A8'-PM-1, and the compound of formula A9'-PM-1 is prepared; or the compound of formula A8'-PM is a compound of formula A8'-PM-2, and the compound of formula A9'-PM-2 is prepared; or the compound of formula A9'-PM-2 is contacted with an ethyl derivative, and the compound of formula A9'-PM-1 is prepared by nucleophilic substitution and reductive amination; Wherein, R2 is defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R10~R12 and n are defined as described in Request 17; W, Y, R8 and R9 are defined as described in Request 42.
63. A method for preparing a compound of formula A9, a compound of formula A9', a compound of formula A9-P, a compound of formula A9'-P, a compound of formula A9-M, a compound of formula A9'-M, a compound of formula A9-PM, a compound of formula A9'-PM, or an optical isomer thereof, comprising the following steps: subjecting a compound of formula AA8 to a dehydroxylation protection reaction to prepare a compound of formula A8, and then subjecting the compound of formula A8 to a cyclization reaction to prepare a compound of formula A9; wherein, When R14 is -O-(S=O)2-R15, the preparation method of compound A9 does not involve the step of preparing compound A8 from compound AA8, but directly performs a cyclization reaction on compound AA8 to prepare compound A9; compound A8' is subjected to a dehydroxylation protection reaction to prepare compound A8', and then compound A8' is subjected to a cyclization reaction to prepare compound A9'; wherein, when R14 is -O-(S=O)2-R15, the preparation method of compound A9' does not involve the step of preparing compound A8' from compound AA8, but directly performs a cyclization reaction on compound AA8' to prepare compound A9'. Compound A8-P is prepared by dehydroxylation of compound AA8-P, followed by cyclization of compound A8-P to prepare compound A9-P. When R14 is -O-(S=O)2-R15, the preparation method of compound A9-P skips the step of preparing compound A8-P from compound AA8-P, and directly cyclizes compound AA8-P to prepare compound A9-P. Similarly, compound A8'-P is prepared by dehydroxylation of compound AA8'-P, followed by cyclization of compound A8'-P to prepare compound A9'-P. When R14 is -O-(S=O)2-R15, the preparation method of compound A9'-P skips the step of preparing compound A8'-P from compound AA8'-P, and directly cyclizes compound AA8'-P to prepare compound A9'-P. Compound A8-M is prepared by dehydroxylation of compound AA8-M, followed by cyclization of compound A8-M to prepare compound A9-M. When R14 is -O-(S=O)2-R15, the preparation method of compound A9-M bypasses the step of preparing compound A8-M from compound AA8-M, and directly proceeds to cyclization of compound AA8-M to prepare compound A9-M. Similarly, compound A8'-M is prepared by dehydroxylation of compound AA8'-M, followed by cyclization of compound A8'-M to prepare compound A9'-M. When R14 is -O-(S=O)2-R15, the preparation method of compound A9'-M bypasses the step of preparing compound A8'-M from compound AA8'-M, and directly proceeds to cyclization of compound AA8'-M to prepare compound A9'-M. The compound of formula AA8-PM was subjected to a dehydroxylation protection reaction to prepare compound A8-PM, and then the compound of formula A8-PM was subjected to a cyclization reaction to prepare compound A9-PM.Wherein, when R14 is -O-(S=O)2-R15, the preparation method of the compound of formula A9-PM does not involve the step of preparing the compound of formula A8-PM from the compound of formula AA8-P, but directly performs a cyclization reaction on the compound of formula AA8-PM to prepare the compound of formula A9-PM; wherein, the compound of formula AA8'-PM undergoes a dehydroxylation protection reaction to prepare the compound of formula A8'-PM, and then performs a cyclization reaction on the compound of formula A8'-PM to prepare the compound of formula A9'-PM; wherein, when R14 is -O-(S=O)2-R15, the preparation method of the compound of formula A9'-PM does not involve the step of preparing the compound of formula A8'-PM from the compound of formula AA8'-PM, but directly performs a cyclization reaction on the compound of formula AA8'-PM to prepare the compound of formula A9'-PM. Wherein, R1~R2 are defined as described in Request 1; R5~R7 and m are defined as described in Request 6; R10~R12 and n are defined as described in Request 17; R14 and R15 are defined as described in Request 39; W, Y, and Z are defined as described in Request 42.
Citation Information
Patent Citations
Fused pyridone compound, and preparation method therefor and use thereof
WO2021052499A1
Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
WO2021083167A1
Octahydropyrazinodiazanaphthyridine dione compounds
WO2021197499A1
